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Zusammenfassung 
___________________________________________________________________________ 
 
Jedes Jahr erleiden weltweit circa 22 Menschen pro eine Million Einwohner eine 
Querschnittslähmung, die bei den  Betroffenen zu dauerhaften Behinderungen und 
erheblichen Einschränkungen im Alltag führt. Die schwerwiegenden Defizite nach einer 
Querschnittslähmung, darunter Lähmungen und chronischer Schmerz, sind darauf 
zurückzuführen, dass geschädigte Axone im Rückenmark kaum regenerieren und es auch nur 
in geringem Ausmaß zur funktionellen Reorganisation der noch erhaltenen 
Nervenverbindungen kommt. Im Unterschied zum peripheren Nervensystem, wo zerstörte 
Nervenfasern erfolgreich regenerieren, ist die axonale Regenerationskapazität des zentralen 
Nervensystems (ZNS) spärlich  ausgeprägt. Zwar konnte durch intensive Forschung im 
Verlauf der letzten Jahrzehnte eine Anzahl von „extrinsischen“ wachstumshemmenden 
Molekülen von Gliazellen und der extrazellulären Matrix des ZNS identifiziert werden. Es gibt 
jedoch zunehmend Hinweise darauf, dass zahlreiche dieser „extrinsischen“ Signale letztlich 
in „intrinsische“ Signalwege der Neuronen selbst einmünden um schließlich die Transkription 
neuronaler Gene zu verändern. Einer der interessantesten intrinsischen Regulatoren 
axonaler Regeneration ist der Transkriptionsfaktor ´Signal transducer and activator of 
transcription 3´ (STAT3). In dieser Arbeit habe ich mithilfe moderner In-vivo-Mikroskopie 
sowie viraler Gentherapie in Spinalganglien genetisch veränderter Mäuse zum ersten Mal die 
entscheidende Rolle von STAT3 in der intrinsischen Regulation axonaler Regeneration in vivo 
identifizieren können. So konnte nachgewiesen werden, dass die nur rudimentär 
ausgeprägte Regeneration der zentralen Fortsätze der Neuronen in den Spinalganglien mit 
einer fehlenden Induktion von STAT3 in den entsprechenden Ganglien einhergeht. Durch 
Überexpression von STAT3 mittels rekombinanter Adeno-assoziierter Viren in zervikalen 
Spinalganglien konnte zwei Tage nach Läsion das Auswachsen von Axonen sowie das 
Aussprießen von  Kollateralen um mehr als das Vierfache gesteigert werden. Darüber hinaus 
konnte mittels repetitiver Multiphotonenmikroskopie einzelner fluoreszenzmarkierter Axone 
gezeigt werden, dass die Überexpression von STAT3 nur in der Frühphase (2-4 Tage) die 
axonale Wachstumsgeschwindigkeit erhöhen konnte, nicht aber zu einem späteren 
Zeitpunkt (4-10 Tage) nach Läsion. Um die Hypothese zu überprüfen, dass die fehlende 
Aufrechterhaltung des axonalen Wachstums durch Kontakt der aussprossenden Axone mit 
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einem zunehmend inhibitorischen ZNS-Milieu bedingt ist, wurde die Überexpression von 
STAT3 zusätzlich mit der Applikation von Chondroitinase ABC, einem Enzym, das die 
inhibitorischen Moleküle der glialen Narbe neutralisieren kann, kombiniert. Dabei konnte ich 
zeigen, dass das durchschnittliche Wachstum von Axonen um mehr als das Zweifache 
gesteigert werden konnte. 
Aus den Ergebnissen meiner Versuche konnte ich mehrere Schlussfolgerungen ziehen: 
Erstens konnte ich STAT3 als effektiven Initiator axonalen Wachstums nach 
Rückenmarksläsion identifizieren. Zweitens wurde nachgewiesen, dass STAT3 selektiv 
Wachstum in der frühen Phase reguliert, nicht jedoch zu späteren Zeitpunkten. Daraus folgt, 
dass das axonale Regenerationsprogramm aus mindestens zwei verschiedenen, molekular 
distinkten Phasen besteht. Mit STAT3 wurde zum ersten Mal ein phasenspezifischer 
Regulator der axonalen Regeneration entdeckt. Abschließend konnte gezeigt werden, dass 
synergistische Therapien - wie hier durch die Kombination von STAT3 und Chondroitinase 
ABC belegt wurde - axonales Wachstum zusätzlich verbessern.  Die gewonnenen Einblicke in 
die Mechanismen axonaler Regeneration geben Grund zur Hoffnung, dass in der Zukunft 
effektive Kombinationstherapien für Querschnittsgelähmte entwickelt werden können. 
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Summary 
___________________________________________________________________________ 
 
Worldwide each year twenty-two in one million people experience a spinal cord injury (SCI) 
leading to permanent disability and tremendous restrictions in daily life activities. The severe 
and persistent functional deficits resulting from SCI such as paralysis and chronic pain are 
due to the limited repair of damaged axonal connections and the poor reorganization of 
spared nerve connections in the central nervous system (CNS). Whereas damaged axons in 
the peripheral nervous system (PNS) regenerate successfully, CNS axons fail to regrow. 
Intensive research over the last decades has identified a number of growth inhibitory 
molecules in the CNS environment and there is evidence that many of these extrinsic cues 
converge on intrinsic neuronal signaling pathways that eventually alter gene transcription. 
One of the most interesting intrinsic regulators of axonal regeneration is the transcription 
factor ‘signal transducer and activator of transcription 3’ (STAT3).  
In this study, I used time-lapse in vivo imaging as well as viral gene therapy in dorsal root 
ganglia (DRG) of genetically modified mice to identify STAT3 as a key regulator of axonal 
regeneration in the CNS. I could show that the failure of central DRG branches to regenerate 
is paralleled by the lack of STAT3 induction in the corresponding DRG neurons. 
Overexpression of STAT3 by recombinant adeno-associated viruses in DRG neurons 
increased outgrowth and collateral sprouting of central DRG branches more than fourfold at 
two days after lesion. Furthermore, repetitive multiphoton imaging of single fluorescently 
labeled CNS axons revealed that STAT3 overexpression selectively increased the speed of 
axonal growth at early (two to four days) but not at later time points (four to ten days) after 
lesion. As the lack of perpetuation of axonal growth might be due to the fact that 
regenerating axons encounter an increasingly growth inhibitory CNS environment, I 
combined viral STAT3 supplementation with the intrathecal application of chondroitinase 
ABC, an enzyme neutralizing the inhibitory molecules of the glial scar. I could show that the 
average axonal outgrowth ten days after lesion was increased more than twofold. Several 
conclusions can be drawn: First, STAT3 is a potent initiator of neurite outgrowth in vivo. 
Second, STAT3 selectively regulates early growth initiation but not later axon elongation 
implying that axonal regeneration consists of at least two molecularly distinct phases. With 
STAT3, I identified for the first time a phase-specific regulator of axonal outgrowth. Last, 
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combination of STAT3 as an “initiator of regeneration” with synergistic treatments such as 
chondroitinase ABC that improve axon elongation raises the hope for promising combination 
therapy approaches in the future treatment of spinal cord injury.  
 
 Introduction 1 
 
1 Introduction 
___________________________________________________________________________ 
1.1 Epidemiology, etiology and clinical picture of spinal cord injury  
 
The earliest known description of spinal cord injury was found in an ancient Egyptian text 
from the Edwin Smith Surgical Papyrus stating that: “When you examine a man with a 
dislocation of a vertebra of his neck, and you find him unable to move his arms and his 
legs…..Then you have to say: A disease one cannot treat” (Case et al., 2005). 
Until now, spinal cord injury (SCI) has remained a life changing event commonly resulting in 
irreversible neurological impairment affecting motor, sensor and autonomous functions. The 
worldwide incidence of SCI is about 22 per million population (source: International 
Campaign for Cures of Spinal Cord Injury Paralysis [ICCP]) and most cases result from 
accidents in sports and traffic, falls and violence (Devivo 2012). Young people, particularly 
men in their mid twenties, are affected which generates – apart from the personal 
consequences for the patient – immense costs in terms of medical care and social welfare.  
Upon spinal trauma, when the spinal cord is locally damaged and bundles of axons are 
sheared, the neuronal flow of information from the periphery to the brain and vice versa is 
interrupted. Dependent on the level and the completeness of the injury, patients present 
with motor paresis (mostly para- or tetraplegia), abrogated sensation and autonomous 
dysregulation (e.g. postural hypotension, poikilothermia, sexual dysfunction and bowel and 
bladder paralysis). Moreover, patients suffer from chronic pain (s. Fig. 1-1).  
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Fig. 1-1 Spinal cord injury 
(A) The spinal cord as part of the central nervous system (green) transmits motor signals from the brain to 
the periphery via spinal nerves and sends information received from the peripheral nervous system (yellow) 
to the brain. (B) Motor deficits depending on the level of spinal cord injury. B modified from Thuret et al., 
2006. 
 
1.2 Pathophysiology and clinical management of SCI  
 
The mechanical tissue damage upon trauma of the spinal cord is followed by numerous, only 
incompletely understood mechanisms such as local ischemia, edema formation, disturbance 
of ion homeostasis, release of free oxygen radicals and excitotoxins as well as recruitment of 
peripheral inflammatory cells (Schwab et al., 2006; Oyinbo 2011). Astrocytes and microglia 
become reactive and form a scar around the lesion site, together with extracellular 
substances such as chondroitin sulfate proteoglycans (CSPGs) and laminin. Within several 
weeks, macrophages clear the tissue debris and a fluid-filled cyst surrounded by scar tissue 
cells develops (Schwab et al., 1996; Bareyre et al., 2003; Schwab et al., 2006). 
The acute spinal cord injury initially requires intensive medical care, as it can lead to 
cardiovascular, pulmonary and gastrointestinal complications dependent on the level of the 
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lesion. For example, high cervical lesions can cause pulmonary problems that might require 
rapid-sequence intubation and lesions above level T6 result in impaired sympathetic 
innervation of the heart leading to bradycardia. Urinary catheterization is needed to avoid 
bladder distension and secondary bladder infections. Furthermore, patients should receive 
thromboprophylaxis due to immobilization and pain killers should be applied early enough 
to avoid chronification of pain (source: http://www.uptodate.com). Besides, according to a 
recent meta-analysis, surgical stabilization and decompression of the spinal cord should be 
considered in all patients from eight to twenty-four  hours following acute traumatic SCI 
(Furlan et al., 2011) to promote neurologic improvement. Moreover, in many therapeutic 
centers, acute interventions involve application of methylprednisolone as a standard 
treatment. Methylprednisolone has been found to improve clinical outcome by reducing the 
secondary damage including cytotoxic edema, inflammation and release of free radicals. 
Ideally, it is administered at high-dose (30 mg/kg) for twenty-three hours and started within 
the first eight hours of injury (Bracken 2002; Bracken 2012). After this early pharmacological 
intervention, further therapy is limited to physiotherapy, which the patient should undergo 
as early as possible (Edgerton et al., 2006; Mehrholz et al., 2008). In this context, robot-
assisted walking training might turn out to significantly ameliorate motor function (Dietz 
2010; Wirz et al., 2011). 
 
1.3 Preclinical and clinical trials in the field of SCI 
 
To improve future treatment of SCI in humans, many preclinical and clinical trials have been 
performed which target different physiological mechanisms (Fehlings et al., 2005; Schwab et 
al., 2006; Hawryluk et al., 2008; Kwon et al., 2011). The table below (s. Tab. 1-1) summarizes 
some well investigated targets. However, none of these approaches has so far achieved 
resounding therapeutic success. The modest or missing effects of these studies on clinical 
outcome emphasize even more the importance of better understanding the underlying 
mechanisms of SCI to provide better treatment in the future. 
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Non-invasive approaches 
Substance/ 
Method 
Mechanism Status of the study and results Reference 
Erythropoietin 
(EPO) 
Neurons and astrocytes 
both express and respond 
to EPO. Amongst others, 
EPO drives intracellular 
anti-apoptotic signaling 
cascades and reduces 
ischemic damage by 
autoregulation of blood 
flow. 
Studies investigating behavioral and 
histological outcome after EPO treatment 
in rats have yielded inconsistent results. 
The only human trial found on databases 
has recently been suspended (Italian 
multicenter Phase 3 study). 
(Goldman et al., 
2002; Carelli et 
al., 2011; Kwon 
et al., 2011) 
http://www.clinic
altrials.gov 
Systemic 
hypothermia 
Hypothermia has 
neuroprotective effects as 
it maintains intracellular 
ATP concentrations by 
slowing down enzymatic 
activity. 
In rats, reduced apoptosis and tissue 
damage have been found. Results for 
hindlimb motor function are 
contradictory. Clinical trials and case 
reports show trend towards functional 
improvement, randomized multicenter 
trials are still pending. 
(Kwon et al., 
2008; Dietrich et 
al., 2011; Kwon 
et al., 2011) 
Minocycline Minocycline exerts anti-
inflammatory and anti-
apoptotic actions. 
The results of a phase II placebo-
controlled randomized trial of minocycline 
in an acute spinal cord injury model could 
not establish the efficacy of minocycline 
that has been shown in the majority of 
animal studies. 
(Kim et al., 2009; 
Kwon et al., 
2011; Casha et 
al., 2012) 
Riluzole Riluzole decreases 
excitotoxicity by blocking 
voltage-sensitive sodium 
channels and antagonizing 
presynaptic calcium-
dependent glutamate 
release.  
In rats, there is preclinical evidence for 
improved tissue protection and 
ameliorated locomotor scores as well as 
temporally limited effect on spasticity. 
Clinical studies are not yet open for 
patients.  
(Cadotte et al., 
2011; Kwon et 
al., 2011) 
http://www.clinic
altrials.gov 
Invasive approaches  
Substance/ 
Method 
Mechanism Status of the study and results Reference 
Chondroitinase 
ABC 
Enzyme digesting growth 
inhibitory chondroitin 
sulfate proteoglycans in 
the scar after SCI. More 
information s. section 
1.4.1.  
Intrathecal application of chrondroitinase 
ABC improves axonal regeneration and 
neuroprotection of injured fibers, 
promotes sprouting/plasticity of uninjured 
tracts and ameliorates motor function. 
Clinical trials have not yet been started. 
(Bradbury et al., 
2011; Kwon et 
al., 2011) 
Anti-Nogo 
approaches 
Mainly antibodies that 
target Nogo-A which is 
present in growth- 
inhibitory myelin of the 
CNS. More information s. 
section 1.4.1.   
Intrathecal application of anti-Nogo-A 
antibody in animal models showed 
upregulation of growth-specific proteins, 
enhanced sprouting of fibers and the 
formation of new functional connections. 
A Phase II trial is currently ongoing. 
(Bareyre et al., 
2002; Zorner et 
al., 2010) 
Anti-Rho 
approaches 
The Rho signaling pathway 
regulates the cytoskeleton 
and exerts an important 
inhibitory role in neuronal 
growth 
In animal models there is increased axonal 
sprouting and motor improvement; A 
phase I/II clinical trial of a recombinant 
Rho protein antagonist in acute spinal 
cord injury suggested slightly increased 
neurological recovery.  
(Dergham et al., 
2002; Fehlings et 
al., 2011; Kwon 
et al., 2011) 
Activated 
macrophages 
Activated macrophages 
eliminate growth 
The results of a phase 2 randomized 
controlled multicenter trial could not 
(Rapalino et al., 
1998; Schwab et 
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inhibitory myelin debris; 
They exert 
neuroprotective and anti-
excitatory functions 
support the promising results from animal 
models. 
al., 2006; 
Lammertse et al., 
2012) 
Olfactory 
ensheathing 
cells 
These cells have growth 
permissive properties; 
Together with 
regenerating axons they 
seem to migrate through 
an unfavorable CNS 
environment. 
No or little effects concerning functional 
recovery in a phase 1 trial could be found. 
(Ramon-Cueto et 
al., 1998; Dobkin 
et al., 2006; 
Mackay-Sim et 
al., 2008; 
Chhabra et al., 
2009; Lima et al., 
2010) 
Stem cells 
(neuronal and 
mesenchymal 
stem cells) 
Stem cells integrate into 
the damaged host spinal 
cord to replace glia and 
neurons. 
Various studies in rodents and primates 
showed that stem cells reduce apoptosis, 
promote regeneration by directly 
inhibiting growth inhibitors in scar and 
myelin and replace lost cells by 
differentiating into mature 
oligodendrocytes. However, the first 
clinical trial with human embryonic stem 
cells has been suspended. 
(Tetzlaff et al., 
2011; Frantz 
2012; Sakai et al., 
2012; Snyder et 
al., 2012) 
 
Tab. 1-1 Non-comprehensive overview of selective non-invasive and invasive therapeutic approaches in 
SCI therapy 
 
1.4 The failure of successful axonal regeneration in the central 
nervous system 
 
Although SCI patients can have long life expectancies due to improved intensive medical 
care and early mobilization, they still suffer from life-long neurological deficits as the spinal 
cord lacks the capacity to repair injured nerve connections. In contrast to nerve fibers in the 
spinal cord, peripheral nerves, however, can recover successfully from damage: After 
peripheral nerve injury, lesioned axons form so called sprouts at the proximal stump and 
keep growing until they enter the distal stump. They show impressive growth rates from 1-4 
mm/d (Hoke 2006).  
Thus, the question of why axons regenerate in the peripheral nervous system (PNS), but not 
in the central nervous system (CNS) has been in the focus of intensive research over the last 
decades. It has been found that two main obstacles define the poor regeneration in the CNS: 
 a) The growth inhibitory CNS environment and  
 b) The insufficient activation of the intrinsic neuronal growth program upon lesion. 
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1.4.1 The growth inhibitory CNS environment 
 
The environment after a CNS lesion strongly contrasts with the situation seen after axonal 
damage in the PNS: After lesion of a peripheral nerve, axons distal to the injury degenerate 
(Wallerian degeneration) and macrophages infiltrate the area of injury to remove myelin and 
axonal debris. Besides, Schwann cells dedifferentiate within twenty-four to twenty-eight 
hours from myelinating to non-myelinating cells to help macrophages in clearing up myelin. 
In addition, they proliferate and form the so called bands of Büngner to guide sprouting 
axons from the proximal stump into and through the endoneural tubes of the distal nerve 
stumps. Once, the axon tip has reached the stump and thus successfully re-innervated an 
end organ, the surrounding Schwann cells start synthesizing myelin sheaths (Fenrich et al., 
2004; Johnson et al., 2005). Upon axon injury, Schwann cells switch their gene expression 
program to promote a pro-regenerative environment. This includes downregulation of 
myelin genes and upregulation of regeneration-associated genes (RAGs) transcribing for 
growth-associated protein-43 (GAP-43), neurotrophic factors including neurotrophins (NGF, 
NT-3, NT-4 and BDNF) and their receptors, neuropoeitic cytokines (e.g IL-6, LIF), IGF-I, IGF-II 
and GDNF. Also, they enhance expression of cell adhesion molecules such as L1CAM, N-CAM 
and N-cadherin which guide growth towards the distal nerve stump by enabling adhesion 
between axons and Schwann cells (Fenrich et al., 2004). A recent study demonstrated that 
also fibroblasts play a key role when accumulating at the lesion side to sort Schwann cells 
into cords (Parrinello et al., 2010). Upon this interaction, the Schwann cell cords then guide 
axonal regrowth across the wound site. Moreover, extracellular matrix proteins including 
laminin, fibronectin and collagens are secreted to promote the function of the basement 
membrane (Fu et al., 1997; Fenrich et al., 2004; Johnson et al., 2005). All together, a 
permissive physical matrix can form around the side injury enabling axonal attachment and 
growth. 
Not so in the CNS (s. Fig. 1-2): Oligodendrocytes do not dedifferentiate the way Schwann 
cells do. They don’t form bands of Büngner to bridge the lesion and to guide the axon. 
Moreover, oligodendrocytes and microglia sequester myelin debris not only much slower 
but also much more incompletely than macrophages and Schwann cells do in the PNS. 
Instead, oligodendrocytes continue to synthesize myelin and its associated growth inhibitors 
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(Filbin 2003; Fenrich et al., 2004). The most prominent myelin inhibitors are Nogo-A, myelin-
associated glycoprotein (MAG) and the oligodendrocyte myelin glycoprotein (OMgp).  
 
 
Fig. 1-2 The inhibitory CNS environment 
Schematic representation of the injury site in the spinal cord showing main growth inhibitors such as myelin 
associated inhibitors (e.g. Nogo) and Chondroitin sulfate proteoglycans (CSPGs) as part of the extracellular 
matrix of the scar. Illustration modified from Yiu et al., 2006.  
 
In line with this, blockade of Nogo-A by IN-1 antibody has been shown to allow axonal 
growth on myelin in vitro and in vivo (Caroni et al., 1988; Schnell et al., 1990) moving 
treatment strategies targeting Nogo-A into promising clinical trials in patients with acute SCI 
(s. Tab. 1-1). 
 
Apart from persisting myelin, the formation of glial scar is the main barrier for regeneration 
in the CNS. Ineffective removal of growth inhibitory myelin proteins stimulates the 
proliferation of astrocytes. Latter ones gradually form a glial scar which is not only a strong 
 Introduction 8 
 
physical but also chemical barrier for growing axons. The molecules of the extracellular 
matrix of the glial scar have been shown to be highly growth inhibitory. Particularly the 
family of chondroitin sulfate proteoglycans (CSPGs) produced by astrocytes have been 
shown to be highly growth inhibitory (Silver et al., 2004; Bradbury et al., 2011): In vitro by 
repelling growing axons and inhibiting growth promoting molecules including laminin, 
fibronectin and L1 (Dou et al., 1994; Snow et al., 1996) as well as in vivo where development 
of dystrophic growth cones in regenerating axons was correlated with upregulation of CSPGs 
(Davies et al., 1997; Davies et al., 1999).  
Addressing the growth inhibitory potential of CSPGs, their degradation has been in the focus 
of investigation (s. Tab. 1-1). The enzyme chondroitinase ABC extracted from the bacterium 
Proteus vulgaris has turned out to remove the chondroitin sulfate glycosaminoglycan (CS-
GAG) chains from the CSPG core protein and thus making the CSPGs less inhibitory (Silver et 
al., 2004). After promising experiments in vitro, Lemons and colleagues first showed that 
chondroitinase ABC (ChABC) can degrade CSPGs in scar tissue when applied to spinal cords 
of contusion injured rats (Lemons et al., 1999). In 2002, Bradbury and colleagues 
demonstrated that intrathecal injection of chondroitinase ABC into a lesioned spinal cord 
promoted axonal sprouting and elongation in dorsal columns and corticospinal tracts. More 
importantly, a significant improvement in functional locomotor and proprioceptive behavior 
was observed (Bradbury et al., 2002).  
 
1.4.2 The insufficient activation of the intrinsic neuronal growth program 
upon injury in the CNS 
 
Apart from the growth permissive environment, successful axonal regeneration is also 
dependent on the growth capacity of the injured neuron. Eventually, neurons need to 
convert from the “transmitting” into the “growth” mode.  
In contrast to neurons in the CNS, lesioned neurons in the PNS undergo this “switch” which 
is carried out by altered gene expression: In the PNS, nerve injury not only leads to glial but 
also to neuronal upregulation of regeneration-associated genes (RAGs) including genes 
encoding for cytoskeletal proteins like tubulin and actin and the well studied growth-
associated proteins GAP-43 and CAP-23 (cytoskeleton-associated protein-23). The latter two 
are involved in actin accumulation and dynamics and are predominantly found in growth 
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cones where they mediate growth cone elongation (Skene 1989; Benowitz et al., 1997; Frey 
et al., 2000; Caroni 2001).  
Besides, peripherally injured neurons start expressing proteins that are crucial for 
interactions between growth cones and Schwann cells: They upregulate receptors for 
neurotrophic factors released by Schwann cells and the neurons themselves release proteins 
such as neuregulin that – by binding to the erb receptor of Schwann cells – allow close 
interactions between neurons and glia. Moreover, adhesion molecules and integrins in the 
growth cone are upregulated to enable its extensions on the surfaces of Schwann cells and 
basal lamina (Fenrich et al., 2004; Raivich et al., 2007).  
 
The following sections now explain  
 
1) how the intrinsic neuronal growth program is induced in the PNS 
2) how the understanding of 1) has already helped to develop approaches that aim to 
mimic the intracellular growth permissive situation in the CNS and eventually support 
lesioned CNS axons to regrow.  
3) how all the injury signals described in 1) eventually contribute to axonal outgrowth 
 
1.4.2.1  Induction of the intrinsic neuronal growth program after a PNS lesion 
As previously mentioned, neurons alter their gene expression pattern when switching to the 
growth mode. To eventually initiate this transcription program, injury induced signals from 
the lesion site need to be transmitted to the nucleus (s. Fig. 1-3). In the following the 
complex mechanisms of injury induced retrograde signaling are briefly outlined (Ambron et 
al., 1996; Rossi et al., 2007; Rishal et al., 2010): 
 
1.4.2.1.1 Early injury induced signaling 
Immediately upon injury, a burst of voltage-gated sodium channel dependent action 
potentials is generated at the injury site propagating to the cell body where calcium 
channels are opened. The calcium influx then activates among others protein kinases A (PKA) 
and C (PKC) and Ca2+/calmodulin-dependent protein kinases II and IV (CaM kinases II and IV) 
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which in turn regulate the actin cytoskeleton as well as growth related transcription factors 
such as CREB (Ambron et al., 1996; Swulius et al., 2008). Spira and colleagues could show 
that intracellular increase of calcium at the lesion site itself induced localized proteolysis of 
the membrane skeleton (spectrin) and cytoskeleton (actin and microtubules) by calpain 
proteases. The localized proteolysis is a prerequisite to restructure the cytoskeleton which in 
turn marks an important step during growth cone formation where post-Golgi vesicles 
supply membrane material (Spira et al., 2001; Bradke et al., 2012). In line with this, 
tetrodotoxin, a sodium channel blocker, eventually leads to reduced calcium influx and its 
related processes (s. above) which in turn goes along with reduced neurite regeneration 
(Mandolesi et al., 2004). Conversely, electrical stimulation accelerates neurite outgrowth 
after nerve transection (Brushart et al., 2002). However, the role of calcium and electrical 
stimulation is complex and remains ambiguous (s. section 1.4.2.2). Apart from calcium, also 
cAMP – activated by peptide hormones from interneurons and also by calcium – is an 
integral molecule that determines the regenerative potential already at early phases of 
regeneration. After peripheral nerve injury, cAMP levels are elevated and by activating the 
transcription factor CREB via PKA they contribute transcription-dependently to growth 
initiation (Ambron et al., 1996).  
 
1.4.2.1.2 Interruption of constitutive retrograde signaling (“negative signals”) 
Once a neuron is connected with its target, signals originating from the target travel 
retrogradely to the cell body to turn down axonal growth programs in order to enable 
establishment of synaptic connections (Abe et al., 2008). After lesion, the retrograde 
signaling from the peripheral targets is interrupted and these “negative signals” cannot 
longer reach the cell body. They are called “negative signals” as they are present in intact 
neurons and normally suppress the cell body response, but when interrupted they signalize 
injury to the cell body and thus induce regeneration (Zigmond 2011). The molecular 
mediators of this mechanism, however, are not securely identified. Neurotrophins, 
particularly nerve growth factor (NGF), have been suggested (Raivich et al., 2007; Rishal et 
al., 2010): For example, reduction of NGF with an antiserum induced axotomy-like changes 
in neuropeptide expression in intact sympathetic and sensory neurons (Shadiack et al., 
2001). In line with this, continuous infusion of NGF to injured neurons delayed regeneration 
(Gold 1997). Interestingly, neurotrophins have been broadly shown to promote axonal 
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regeneration (Cui 2006; Lu et al., 2008). These contradictory findings might be based on 
different roles of neurotrophins at different time points. Loss of neurotrophic support might 
help inducing growth, whereas gradual increase in neurotrophins and their receptors 
stimulate growth in the later course of regeneration (source: Tuszynski, Mark H.,  Kordower, 
Jeffrey H.,Ed. CNS Regeneration: Basic Science and Clinical Advances. London: Academic 
Press, 2nd edition 2008.).  
 
1.4.2.1.3 Induction of growth-promoting signals (“positive signals”) 
Following the early phase of injury induced changes (s. above), a large group of “positive 
retrograde injury signaling” molecules is activated by calcium and other still unknown 
mechanisms. They are named “positive signals” as they are not active in intact neurons but 
produced upon axotomy to trigger the cell body response. The activated molecules such as 
the transcription factor NF-κB (nuclear factor 'kappa-light-chain-enhancer' of activated B-
cells) and mitogen-activated protein kinases (MAPKs) are microtubule-dependently 
transported towards the cell body where they initiate transcriptional processes. The MAPKs 
have become interesting candidate regulators of axonal regeneration, as exemplified by the 
following: Activation of extracellular signal-regulated kinase (Erk) and c-Jun N-terminal 
kinase (JNK) – two members of the MAPKs – and their interactions with the dynein/dynactin 
retrograde transport seem to be crucial for axonal regeneration (Abe et al., 2008). In 
addition, phorphorylated Erk e.g. is detected in axons after peripheral injury (Sheu 2000) and 
inhibition of Erk prevents adult DRG neurons from spontaneously initiating neurites in 
culture (Chierzi et al., 2005). Erk - by turning on the transcription factor CREB [cAMP 
response element-binding protein, (Johannessen et al., 2004)] - and JNK - by activating the 
transcription factors ATF-3 (Activating transcription factor 3) and c-Jun (Lindwall et al., 2005) 
- are directly involved in activating growth promoting transcription factors. Recently, dual 
leucine zipper-bearing kinase 1 (DLK 1), a kinase of a conserved MAPK cascade has been 
found to positively regulate growth cone formation and axonal regeneration (Hammarlund 
et al., 2009; Yan et al., 2009; Ghosh-Roy et al., 2010).  
The molecules are transported towards the cell body in complexes of the retrograde motor 
dynein and proteins such as vimentin as well as the nuclear transport factors importin α and 
β which regulate entering of kinases to the nucleus. Interestingly, importin β and vimentin 
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are synthesized locally upon injury (Rossi et al., 2007). The role of this local de novo protein 
synthesis remains unclear but might contribute to the rapid injury response.  
At later phases of injury signaling consists of pathways triggered by a number of cytokines 
such as IL-6 (interleukin-6) and CNTF (ciliary neurotrophic factor). They are released around 
the lesion sites from surrounding cells but also from the neurons themselves (Cheng et al., 
1997; Zigmond 2011). They trigger intracellular downstream signaling via the JAK/STAT 
pathway resulting in the activation of the transcription factor signal transducer and activator 
of transcription 3 (STAT3). The key role of STAT3 in this context will be discussed later. 
Moreover, neurotrophic factors and neurotrophins are upregulated at the lesion site to 
maintain the neuron in a regenerative mode, initiating intracellular signaling cascades. 
Neurotrophins are released by Schwann cells and macrophages that have become recruited 
to the lesion site as well as by the lesioned neurons themselves, thus exerting autocrine and 
paracrine effects (Cui 2006). Upon binding to their cognate receptors, neurotrophins activate 
PKA and subsequently elevate cAMP levels leading to above described pro-regenerative 
activities. In addition, they activate the Ras/Raf cascade resulting in activating Erk (Ramer et 
al., 2000; Cui 2006). Thus it’s not surprising that many studies have proven growth-
supportive effects of the neurotrophic family, especially when applied with other substances 
in combination (Tuszynski et al., 1995; Lu et al., 2004; Alto et al., 2009).  
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Fig. 1-3 The intrinsic neuronal growth program activated upon peripheral injury  
The early phase of neuronal response upon nerve damage is characterized by injury induced action 
potentials and release of neuropeptides (such as 5-HT) from the environment that act via calcium and cAMP. 
Subsequently, retrograde MAPK and other components activated at the injury site are retrogradely 
transported to the nucleus. Later on, signals from cytokines and growth factors released by the neuron itself 
as well as by surrounding cells such as glia and macrophages arrive at the nucleus. Ultimately, all pathways 
activate transcription factors and alter gene expression resulting in upregulation of growth-associated 
proteins which in turn orchestrate neurite outgrowth. 
 
1.4.2.2 Failed induction of the intrinsic growth program after a CNS lesion 
In contrast to the PNS, where upon injury a cascade of injury signals are relayed to the 
nucleus and RAGs are upregulated as they are during development (Hoffman 2010), there is 
no upregulation of RAGs in the CNS (Plunet et al., 2002; Fenrich et al., 2004). It still remains 
speculative if this lack is due to neuronal inability of activation or transport of signals, failure 
of overcoming growth inhibition due to maturation (Liu et al., 2011) or reduced response to 
injury induced cytokines. However, studies on DRG neurons extending one branch to the 
periphery and the other to the CNS have yielded interesting findings: Lesion of the 
peripheral branch prior to a central branch lesion promotes regeneration of the central 
branch (Richardson et al., 1984; Neumann et al., 1999; Ylera et al., 2009). This phenomenon 
is also termed “conditioning lesion effect”, suggesting that CNS neurons still respond to 
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injury signals; however, only when the intrinsic program is additionally “primed” by a 
peripheral lesion via injury related processes such as retrograde travel of injury signals etc.  
Thus, many efforts have been undertaken to mimic the conditioning lesion effect by 
specifically modifying one of the above described mechanisms. 
Influencing early injury signals has so far led to ambiguous results: Whereas Udina and 
colleagues could show that electrical stimulation of the sciatic nerve promotes regeneration of 
injured central axons of the stimulated neurons (Udina et al., 2008), others have not found 
growth promotion when directly stimulating transected rubrospinal tract axons (Harvey et al., 
2005). These differences might be explained by the fact that in contrast to Harvey’s experiment 
electrical activity in Udina’s experiment mimicked the “conditioning lesion effect”. Addressing 
cAMP, however, has led to more promising findings: cAMP levels can be therapeutically elevated 
by conditioning lesion, by administration of cAMP analogues or by treatment with the 
phosphodiesterase inhibitor rolipram. Interestingly, it does not only increase the neuron’s 
intrinsic growth capacity (s. section 1.4.2.1.1), but does also overcome myelin inhibition both 
in vitro and in vivo, allowing axons to growth through a spinal cord lesion (Qiu et al., 2002; 
Hannila et al., 2008). 
 
1.4.2.3 Molecular anatomy of the intrinsic neuronal growth program  
Experiments trying to mimic the growth pattern seen after peripheral lesions by modulating 
cascades during early injury induced signaling have been performed (s. above). However, 
more recent attempts aim to directly alter the neuronal growth program on the 
transcriptional and translational level where different injury induced signals eventually 
converge.  
Studies investigated gene expression during neuronal development or compared gene 
expression between regenerating neurons and those that did not show regeneration 
(Bareyre et al., 2003; Moore et al., 2011). Not only genes but also some of the transcription 
factors (TFs), that regulate their expression, have been identified. Among them are c-Jun, 
CCAAT-enhancer-binding protein (C/EBP), CREB, STAT3, ATF-3, Sex determining region Ybox 
containing gene 11 (Sox11) transcription factor, Smad1 and the Krüppel-like family of 
transcription factors [KLFs (Moore et al., 2011)]. TFs are proteins that bind to enhancer or 
promoter regions of their target genes and thus regulate gene expression. As a single TF can 
bind to many locations of the DNA, activation of each of the TFs leads to complex alteration 
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in gene expression. A selection of TFs and their role for axon regeneration is exemplified in 
the following (s. Fig. 1-4).  
Mice lacking c-Jun in the CNS showed severe defects upon injury and reduced expression of 
CD44, galanin, and α7β1 integrin, molecules known to be involved in axonal regeneration 
(Broude et al., 1997; Raivich et al., 2004). Knockout phenotype of the C/EBP transcription 
factor leads to decreased expression of the growth-associated genes for GAP-43 and tubulin-
α1, thus attributing C/EBP an essential role for the neuronal injury response (Nadeau et al., 
2005). Another factor, CREB, has been shown to overcome inhibitors in myelin and promote 
spinal axon regeneration in vivo (Gao et al., 2004). CREB activated by PKA and Erk 
(Johannessen et al., 2004) upregulates Tubulin, IL-6 and Arginase, whereas the latter one 
mediates synthesis of polyamines (Gao et al., 2004; Han et al., 2004; Hannila et al., 2008). 
Polyamines interact with cytoskeletal tubulin and might affect as such axonal growth 
(Savarin et al., 2010). Upregulation of Arginase also results in increased synthesis of 
spermidine, a polyamine, which has turned out to promote optic nerve regeneration in vivo 
(Deng et al., 2009). Another study investigated ATF-3 and could demonstrate that its 
overexpression in adult DRG neurons enhances neurite outgrowth in vitro (Seijffers et al., 
2006) and ATF-3 is associated with the induction of growth promoting genes encoding for 
heat shock protein 27 (Hsp27), the small proline-rich repeat protein 1a (SPRR1A) and 
transcription factor c-Jun (Seijffers et al., 2007). Interestingly c-Jun and ATF-3 have been 
shown to co-localize in neurons after injury and co-immunoprecipitate suggesting that they 
act synergistically or even form heterodimers (Moore et al., 2011). Furthermore, Sox11 
transcription factor seems to regulate neurite growth and neuron survival inducing the RAGs 
Microtubule-associated protein (MAP) and β-III tubulin (Bergsland et al., 2006). Also, 
knockdown of Sox11 goes along with increased expression of the pro-apoptotic gene BNIP3, 
decreased expression of the anti-apoptotic gene TANK and a decrease in Arpc3, an actin 
organizing protein that may be involved in axon growth (Jankowski et al., 2006). Another 
group has identified Smad1 to promote axonal growth in adult sensory neurons (Zou et al., 
2009). Very recently, KLFs were identified to regulate intrinsic axon regeneration ability. The 
KLFs are zinc-finger transcription factors that suppress (e.g. KLF4) or enhance (e.g. KLF6) the 
regenerative capacity of CNS neurons (Moore et al., 2009; Tedeschi et al., 2010). A couple of 
their gene targets that are involved in axon regeneration have been identified and include 
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GAP-43 gene and genes important for synaptogenesis and cytoskeletal dynamics (Moore et 
al., 2011).  
 
 
Fig. 1-4 Transcription factors involved in axonal regeneration and their target genes.  
A variety of intracellular signaling molecules implicated in axon regeneration lead to activation of 
transcription factors (in yellow boxes). The transcription factors activate target genes (red) in the nucleus 
and thus promote axonal outgrowth. For example, CREB activates IL-6, Arginase and Tubulin, whereas latter 
ones are involved in local cytoskeleton assembly. More information as well as references about the 
transcription factors shown in the illustration can be taken from the text. Image adapted from Tuszynski, 
Mark H., Kordower, Jeffrey H., Ed. CNS Regeneration: Basic Science and Clinical Advances. London: Academic 
Press, 2nd edition 2008. 
 
On the level of protein translation, the PTEN/mTOR pathway has been found to influence 
protein synthesis and cell growth: Deletion of the phosphatase and tensin homolog (PTEN) 
has been shown to allow robust axon regeneration of the optic nerve, whereas its 
downstream molecule mammalian Target of Rapamycin (mTOR) is positively associated with 
axonal regeneration. mTOR controls protein translation and can regulate microtubule 
assembly and axonal transport (Park et al., 2010). Furthermore, post-translational processes 
 Introduction 17 
 
seem to influence axonal regeneration as exemplified by the anaphase-promoting complex 
(APC) which might degrade pro-regenerative molecules (Lasorella et al., 2006).  
 
1.5 STAT3 
 
Apart from the above mentioned transcription factors, STAT3 has recently emerged as a key 
candidate regulator of axonal regeneration. Before presenting STAT3 in the context of 
axonal regeneration, the STAT family, the JAK/STAT pathway as well as the role of STAT3 
outside the nervous system is briefly outlined.  
 
1.5.1 The STAT family 
 
STAT3 belongs to a family of transcription factors comprising seven members: STAT1, STAT2, 
STAT3, STAT4, STAT6 and the closely related STAT5A and STAT5B. The signal transducers and 
activators of transcription (STATs) range in size from 750 to 950 kDa and share several 
structurally and functionally conserved domains (Becker et al., 1998; Kisseleva et al., 2002; 
Levy et al., 2002): The amino-terminal domain (NH2) is involved in stabilizing dimers and 
importing of the STAT molecule to the nucleus (s. Fig. 1-5); the coiled-coil domain is 
implicated in receptor binding; the DNA-binding domain mediates binding of the STAT 
molecules to the corresponding DNA sequences; the linker domain is involved in nuclear 
export and transcriptional activities and is followed by the Src Homology 2 (SH2) domain, the 
most highly conserved domain which - through its capacity to bind to specific 
phosphotyrosine residues – plays an important role for STAT activation. The transactivation 
domain interacts with proteins that are necessary for binding of RNA-polymerase to DNA. 
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Fig. 1-5 Structure of the STAT3 molecule 
(A) Linear structure of STAT3 and (B) three-dimensional structure of the STAT3 homodimer bound to DNA  
showing the different domains of the STAT3 molecule: Amino-terminal domain, coiled-coil domain (blue), 
DNA-binding region (red), linker domain (green), SH2-domain (yellow) with phosphorylation at a tyrosine 
residue and the transactivation domain. A adapted from Levy et al., 2002. B adapted from Becker et al., 
1998.  
 
1.5.2 The JAK/STAT pathway 
 
STAT3 as well as the other STATs are part of the JAK/STAT signaling pathway (s. Fig. 1-6) 
transmitting extracellular signals to the nucleus (Schindler et al., 1995; Aaronson 2002; 
Kisseleva et al., 2002):  
Neuropoetic cytokines such as IL-6, CNTF, leukemia inhibitory factor (LIF) and oncostatin M 
bind to the ligand binding chain of the gp130 receptor which subsequently dimerizes with 
the signal transducing chain of the receptor unit (Schindler et al., 1995). This configuration 
brings receptor associated Janus kinases (JAKs) mostly JAK1 (Guschin et al., 1995) and JAK2 
into apposition, which can now transphosphorylate each other and thus release their 
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catalytic activity: JAKs phosphorylate a distal cytoplasmic tyrosine residue on the receptor 
thereby creating docking sites for the SH2 domain of STAT3 proteins. Subsequently, STAT3 
proteins which are present in the cytoplasm in inactive form are drawn into the receptor 
complex and are phosphorylated on a single tyrosine residue by the JAKs (Kisseleva et al., 
2002). In doing so, also in STAT3 molecules, docking sites for SH2 domains are created. 
When STAT3 proteins subsequently dissociate from the receptor, the phosphotyrosine 
residues of two STAT molecules are reciprocally recognized: The SH2 domain of one STAT3 
molecule binds to the phosphotyrosine of the other STAT3 molecule, thus forming 
homodimers. These dimers arerapidly transported from the cytoplasm to the nucleus where 
they bind to promotor sequences containing the GAS (gamma activated site) element, the 
pallindromic DNA sequence 5’-TTTCCNGGAAA-3’, and induce gene transcription (Aaronson 
2002; Kisseleva et al., 2002).  
The JAK/STAT pathway is regulated at several levels (Aaronson 2002; Kisseleva et al., 2002): 
MAPK e.g. have been shown to amplify STAT3 signaling by additional phosphorylation on 
serin residues. But there is also negative regulation of the pathway, e.g. phosphatases 
deactivating STATs and JAKs as well as suppressors of cytokine signaling (SOCS) that inhibit 
receptors and JAKs. Besides, nuclear regulators control STAT import and export to and from 
the nucleus and PIAS (Protein inhibitor of activated STATs) prevent STAT3 dimers from 
binding to the DNA.   
A study in human breast cancer cells found that the STAT3 pathway is positively regulated by 
the above mentioned mTOR signaling pathway, whereas PTEN (s. above) served as a 
negative regulator of both STAT3 and mTOR signaling (Zhou et al., 2007).  
Interestingly, upon peripheral nerve injury, it could be shown that STAT3 can be locally 
activated in the axon and retrogradely transported to the nucleus (Sheu 2000; Lee et al., 
2004; Ben-Yaakov et al., 2012). However, gp130/JAK complexes might also be internalized 
and transported to the cell body to activate STAT3 (O'Brien et al., 2007). 
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Fig. 1-6 Activation of the JAK/STAT3 pathway 
The JAK/STAT3 pathway is activated by cytokines e.g. IL-6, CNTF and LIF. In the course of activation, latent 
cytoplasmic STAT3 proteins are recruited and phosphorylated by JAKs. Phosphorylated STAT3 molecules 
dimerize and are translocated into the nucleus where they modulate target genes. 
 
1.5.3 The role of STAT3 outside the nervous system  
 
STAT3 was initially identified in 1994 as an acute-phase response factor activated by IL-6 and 
other gp130- receptor dependent cytokines (Akira et al., 1994; Zhong et al., 1994). To learn 
more about the physiological functions of STAT3, STAT3 knockout mice were generated soon 
after (Takeda et al., 1997): It turned out that these mice differed from all other STAT 
knockouts and died already around embryonic day six indicating an important role of STAT3 
for embryonic development. To study STAT3 mediated processes at later stages of 
development, tissue-specific knockouts were created using the cre-loxP recombination 
system (s. Tab. 1-2): Put under the control of a tissue-specific promotor, the cre recombinase 
is only expressed in the cell population of interest. Wherever it is expressed, the enzyme 
recognizes the loxP sites flanking the STAT3 gene on both sides and excises the DNA 
sequence of STAT3 (s. Fig. 4-12). In most tissues the functions affected by STAT3 deletion 
involve cell survival and proliferation (Levy et al., 2002). 
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Promotor 
for cre  
Target 
tissue/cells 
Phenotypes Reference 
K5 keratinocytes 
 
Altered migration: disrupted wound repair, impaired 
keratinocyte migration and hair cycle; spontaneous 
development of ulcers. However, normal proliferation 
and development of epidermis and hair follicles. 
 
(Sano et al., 
1999; Sano et 
al., 2008) 
K5  Thymus 
epithelium 
Altered survival: severe thymic hyoplasia, increased 
susceptibility to apoptosis-inducing agents such as 
steroids  
(Sano et al., 
2001) 
Blg Mammary 
epithelium 
Altered apoptosis: delayed mammary involution  (Chapman et 
al., 1999).  
 
 
Mx Liver Impaired acute-phase response, similar to the 
phenotype of IL-6 knockout mice 
(Alonzi et al., 
2001) 
Lck T-lymphocytes Altered survival/proliferation: impaired IL-6 dependent 
T-cell survival and reduced IL-2 induced proliferation 
(Akaishi et al., 
1998; Takeda 
et al., 1998).   
Mlys Monocytes/ 
Neutrophils 
Hypersensitivity to endotoxin shock resulting in 
augmented production of inflammatory cytokines such 
as IL-1, IL-6 and IFNγ as a consequence of impaired IL-10 
function; chronic colitis; imbalanced T-cell differentiation 
towards the Th1 type 
(Takeda et al., 
1999) 
 
Tab. 1-2 Tissue-specific  STAT3-deficient phenotypes outside the nervous system 
Tissue-specific STAT3 deletion was achieved by taking advantage of the cre/loxP system. Table modified by 
Levy et al., 2002. In most tissues the functions affected by STAT3 deletion involve cell survival and 
proliferation 
 
1.5.3.1 STAT3 in cancer 
Along with its permissive role for survival and proliferation, STAT3 is also closely associated 
with oncogenesis (Bromberg 2002): While STAT1 is ascribed a tumor suppressor role, both 
STAT3 and STAT5 were found to increase tumor cell proliferation, survival and invasion. 
Constitutive activation of STAT3 has been found in many solid tumors such as breast cancer, 
prostate cancer and melanoma as well as in leukemias and lymphomas. Moreover, STAT3 is 
required for the transformation into malignant cells in some malignancies e.g. breast cancer 
and thyroid cancer. 
Already in 1999, it could be demonstrated, that in patients with multiple myeloma, STAT3 
was constitutively activated in bone marrow mononuclear cells where it induced the 
expression of Bcl-xL (B cell lymphoma extra large protein), an anti-apoptotic protein (Catlett-
Falcone et al., 1999). Until now, many other tumor-associated genes encoding for proteins 
such as survivin and VEGF have been found to be induced by STAT3 (Yu et al., 2009). 
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1.5.4 STAT3 in the context of neuronal survival and regeneration 
 
The role of STAT3 for the nervous system appears very similar to its effects outside the 
nervous system where it supports survival and proliferation. STAT3 is an important player 
during neurodevelopment, where it is e.g. required for axon pathfinding, neurite outgrowth 
and glial cell differentiation (Dziennis and Alkayed 2008). In rodents, STAT3 expression is 
detected in neurons and glia from embryonic day fourteen on with increasing levels up to 
postnatal day twenty-one, when levels start declining (Gautron et al., 2006).  
In addition to its role in the developing nervous system, STAT3 has turned out to be an 
interesting transcription factor in the context of axon regeneration. Several studies 
demonstrate that increased levels of STAT3 expression and phosphorylation are associated 
with axonal regeneration in the PNS: After axotomy in rats, STAT3 phosphorylation is 
induced in facial and hypoglossal neurons already three hours after lesion, whereas this 
response is not found in non-regenerating Clarke’s nucleus neurons (Schwaiger et al., 2000). 
A transient activation of STAT3 is also associated with sprouting of septal neurons after 
entorhinal cortex lesion in rats (Xia et al., 2002). Moreover, a study investigating the 
different spatial and temporal pattern of STAT3 and Erk phosphorylation in rats could show 
that nerve transection induced rapid STAT3 phosphorylation particularly in the proximal site 
adjacent to the injury which decreased to almost baseline when regeneration was complete 
at six weeks (Sheu 2000). Interestingly, STAT3 is activated at the injury site and then 
retrogradely transported to the nucleus (Lee et al., 2004). 
After transection of the sciatic nerve in rats, but not after dorsal column lesion, STAT3 is 
activated in the corresponding DRG (Qiu et al., 2005). Qui and colleagues assumed that 
STAT3 activation was not only necessary for regeneration in the PNS, but also in the CNS. 
This was based on the finding that blockade of STAT3 phosphorylation by the JAK2 inhibitor 
AG490 impaired neurite outgrowth in vitro and compromised dorsal column regeneration 
after a pre-conditioning sciatic nerve transection. Not only in regeneration, but also in 
neuronal survival, STAT3 seems to be a key player: tissue-specific deletion of STAT3 in 
motoneurons from embryonic day twelve on results in reduced facial motoneuron survival 
(Schweizer et al., 2002). Further, a recent study using microarray approaches and subtractive 
hybridization identified STAT3 as a transcription factor that is selectively upregulated after 
PNS injury and a potent promoter of cultured cerebellar granule neurons (Smith et al., 2011).   
 Introduction 23 
 
Apart from regeneration, STAT3 is associated with axonal remodeling in the CNS: Unilateral 
lesion of the CST and application of IN-1 antibody directed against the growth inhibitor 
protein Nogo-A triggered reorganization of the remaining CST fibers. Interestingly, IN-1 
antibody treatment was among others associated with upregulation of STAT3 expression 
(Bareyre et al., 2002).  
Apart from STAT3 itself, various studies investigating molecules that exert their function via 
JAK/STAT pathway such as the neuropoietic cytokines IL-6, CNTF, LIF and SOCS3 highlight 
STAT3 as a good candidate in terms of axonal growth regulation. One study showed that LIF 
activated STAT3 after nerve injury (Rajan et al., 1995) and that sensory neurons of LIF 
deficient mice showed a significantly attenuated growth response upon a conditioning injury 
(Cafferty et al., 2001). Three years later, Cafferty and colleagues demonstrated that in IL-6 
deficient mice, a pre-conditioning injury of the sciatic nerve was followed by a total failure of 
regeneration of dorsal column axons, thus identifying IL-6 as a keyplayer for mediating 
conditioning lesion-induced increase of regeneration of lesioned axons in the CNS (Cafferty 
et al., 2004). This goes along with the finding that sensory axons in IL-6 deficient mice show 
delayed regeneration after crush lesion (Zhong et al., 1999). Interestingly, also hormones 
such as Erythropoietin (Kretz et al., 2005) and IGF-I (Yadav et al., 2005) as well as 
neurotrophins such as NGF (Donnerer et al., 2005) and BNDF (Ng et al., 2006) activate STAT3 
and have been shown to be involved in axonal regeneration and neurite outgrowth. 
Recently, it could be demonstrated that deletion of SOCS3 (an intracellular downregulator of 
STAT3) in adult retinal ganglion cells promotes robust regeneration of injured optic nerve 
axons. This pro-regenerative response could be even enhanced by exogenously delivered 
CNTF to SOCS deficient mice (Smith et al., 2009). Latter finding confirmed previous data 
suggesting a neuroprotective and axon growth promoting role of CNTF (Muller et al., 2007).  
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1.6 Research question 
 
In contrast to the PNS, where damaged axons can regenerate successfully, CNS axons fail to 
regrow. One of the reasons underlying this failure is the insufficient activation of the intrinsic 
neuronal growth program after a central lesion. To jump-start the intrinsic growth program 
after CNS injury we first need to identify its molecular key regulators. Especially transcription 
factors are promising candidate regulators as they can alter the expression of multiple 
downstream genes. The transcription factor STAT3 is a particularly promising candidate 
regulator as its expression correlates with the regenerative response (s. section 1.5.4). 
However, its direct role for axonal outgrowth in vivo has not yet been determined. This study 
now aimed to directly show a) whether and b) when STAT3 affects central axonal 
regeneration in vivo by answering the following specific questions (s. Tab. 1-3): 
 
 
1. Is endogenous STAT3 activation induced after a CNS lesion? 
2. Is STAT3 overexpression by viral gene therapy sufficient to induce outgrowth of CNS 
axons? 
3. How does STAT3 affect different phases of axonal outgrowth in the CNS?  
4. In case STAT3 overexpression positively influences axonal outgrowth in the CNS, can 
axon regeneration even be amplified when viral overexpression of STAT3 is combined 
with the application of chondroitinase ABC? 
 
 
Tab. 1-3 Research questions to be answered in the course of my study 
 
 
To address these questions, I used in vivo timelapse fluorescence microscopy and viral gene 
therapy in transgenic and wildtype mice to investigate the regeneration process of lesioned 
central branches emerging from dorsal root ganglia (DRGs).
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2 Material and Methods 
___________________________________________________________________________ 
2.1 Material 
 
 
1. Materials for surgical experiments 
 
1.1 Reagents  
Ketamine hydrochloride 10% 
(Ketamine) 
Bremer Pharma GmbH, Warburg, Germany 
Xylariem 20 mg (Xylazine) Riemser Arzneimittel AG, Greifswald-Insel Riems, 
Germany 
Forene (Isoflurane) Abbott AG, Baar, Switzerland  
Metacam 1,5 mg/ml Oral Suspension  Boehringer Ingelheim, Ingelheim am Rhein, 
Germany 
Sterile artificial mouse cerebrospinal 
fluid (aCSF) 
Solution A: 
 
8,66 g NaCl (Merck) 
0,224 g KCl (Merck) 
0,206 g CaCl2 · 2H2O 
(Sigma-Aldrich) 
0,163 g MgCl2 · 6H2O 
(Sigma-Aldrich) 
 
dH20 ad 500 ml 
Solution B: 
 
0,214 g Na2HPO4 · 7H2O 
(Merck) 
0,027 g NaH2PO4 · H2O 
(Merck) 
 
dH20 ad 500 ml  
Mixture of solutions A and B in a 1:1 ratio 
Bepanthen Augen- und Nasensalbe  5 
g (eye cream)  
Bayer Vital GmbH, Leverkusen, Germany 
Ringerlösung Fresenius KabiPac 
(Ringer’s solution) 
Fresenius KaBI Dtl., Bad Homburg, Deutschland 
Cutasept F Lösung 250 ml 
(disinfectant spray)  
Bode Chemie GmbH & Co, Hamburg, Germany 
Chondroitinase ABC Sigma-Aldrich, St.Louis (Missouri), USA 
Bovine serum albumin (BSA) Sigma-Aldrich, St.Louis (Missouri), USA 
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1.2 Tools and materials  
Wella contura W7807 (Hair clipper) Wella, Darmstadt, Germany 
Micro Pipettes intraMARK Blaubrand 
(micropipettes/glass capillaries) 
Brand GmbH und Co. KG, Wertheim, Germany 
Syringe 3pc 20 ml Omnifix™ luer slip 
(syringe for virus injection) 
B. Braun Melsungen AG, Melsungen, Germany 
Syringe 3pc 5 ml Omnifix™ luer slip 
(syringe for injection of Ringer’s 
solution) 
B. Braun Melsungen AG, Melsungen, Germany 
BD Plastipak Hypodermic luer slip 
syringe 1 ml (syringe for 
Ketamine/Xylazine injection) 
Becton, Dickinson and Company, Franklin Lakes 
(New Jersey), USA 
Safety-Multifly-Set  (blood collection 
system with needle, butterfly, tube 
and connector to syringe)  
SARSTEDT AG & Co., Nümbrecht, Germany 
Fine Iris Scissors (for dorsal column 
lesion) 
Fine Science Tools GmbH, Heidelberg, Germany 
Feather stainless steel blade (surgical 
blade)  
pfm medical ag, Cologne, Germany 
Noyes Spring Scissors (Large spring 
scissors) 
Fine Science Tools GmbH, Heidelberg, Germany 
Vannas-Tübingen Spring Scissors 
(Small angled spring scissors) 
Fine Science Tools GmbH, Heidelberg, Germany 
Dumont Mini Forceps – Inox Style 3 
(Small forceps)  
Fine Science Tools GmbH, Heidelberg, Germany 
Dumont Mini Forceps – Inox Style 5 
(Small forceps, smaller tip than Inox 
style 3)  
Fine Science Tools GmbH, Heidelberg, Germany 
Hypodermic Needles BD Microlance 
3 30 Gauge (0,3 mm, yellow) for 
subcutaneous injection of Ringer’s 
solution and anesthesia 
Becton, Dickinson and Company, Franklin Lakes 
(New Jersey), USA 
Hypodermic Needles BD Microlance 
3 23 Gauge (0,6 mm, blue) for central 
lesion 
Becton, Dickinson and Company, Franklin Lakes 
(New Jersey), USA 
Olsen-Hegar Needle Holder   Fine Science Tools GmbH, Heidelberg, Germany 
Ethicon Ethilon monofil 6-0 size, 
667H (skin suture) 
Johnson & Johnson Medical GmbH, Norderstedt, 
Germany 
Ethicon Vicryl 4-0 size, MIC101H 
(intracorporal suture) 
Johnson & Johnson Medical GmbH, Norderstedt, 
Germany 
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Autoclip Wound Clip Applier (stapler) Becton, Dickinson and Company, Franklin Lakes 
(New Jersey), USA 
Autoclip Wound Clips, 9 mm (staples) Becton, Dickinson and Company, Franklin Lakes 
(New Jersey), USA 
Sugi (absorbent triangles) Kettenbach GmbH & Co. KG, Eschenburg, Germany  
Metal plate Custom-made 
Cast Alnico Button Magnets 
(magnets) 
Eclipse Magnetics Ltd, Sheffield, UK 
Rubber bands  
Support cushion Custom-made 
Osmotic minipump (Model 1007B) Alzet, Cupertino (California), USA  
Brain Infusion kit 3 Alzet, Cupertino (California), USA 
1.3 Technical devices  
Olympus KL 1500 LCD (cold light 
source for stereo microscopy) 
Olympus UK Ltd KeyMed House, Southend-on-Sea, 
Great Britain 
Olympus Stereo Microscope SZ51 Olympus UK Ltd KeyMed House, Southend-on-Sea, 
Great Britain 
FST 250 Hot Bead Sterilizer (sterilizer 
for surgical instruments)  
Fine Science Tools GmbH, Heidelberg, Germany  
Vertical Micropipette Puller P-30 Sutter Instrument Company, Novato (California), 
USA 
Small Animal Stereotactic Instrument  David Kopf Instruments, Tujunga (California),  USA 
T/Pump (Heating pad)  Gaymar Industries, Orchard Park (New York), USA 
 
 
2. Materials for perfusion and immunohistochemistry 
 
2.1 Reagents   
PFA (paraformaldehyde) 8% PFA (Sigma-Aldrich) in dH2O, heated up 
to 55 °C and stirred additional 10 min, 
filtrated and mixed in a 1:1 ratio with 0,2 M 
PB (Phosphate buffer), pH adjusted to 7,2-
7,8 
Agarose Sigma-Aldrich, St.Louis (Missouri), USA 
Triton X-100 Sigma-Aldrich, St.Louis (Missouri), USA 
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Sucrose Sigma-Aldrich, St.Louis (Missouri), USA 
 EDTA (Ethylenediaminetetraacetic acid) Merck KGaA, Darmstadt, Germany 
Sodium dihydrogen phosphate monohydrate 
(NaH2PO4· H2O, M=137,99 g/mol) 
Merck KGaA, Darmstadt, Germany 
Disodium hydrogen phosphate dihydrate 
(Na2 HPO4· 2H2O ,M=177,99 g/mol) 
Merck KGaA, Darmstadt, Germany 
PBS 10x (phosphate buffered saline), pH= 
7,2/7,4 
2,6 g NaH2PO4 · H2O 
14,4g Na2 HPO4· 2H2O  
87,5g NaCl (Merck)  
dH2O ad 1l 
TBS 10x (Tris buffered saline), pH=7,6 61 g Tris base (121,14 g/mol), (Sigma-
Aldrich) 
90 g NaCl 
dH2O ad 1l 
O,2 M PB (phosphate buffer)  27,598 g NaH2PO4· H2O, 
35,598 g Na2 HPO4· 2H2O 
dH2O ad 1l 
Anti-STAT3 antibody Cell signaling Technology, Danvers 
(Massachusetts), USA 
Anti-P-STAT3 antibody Cell signaling Technology, Danvers 
(Massachusetts), USA 
Goat-anti-rabbit 594 antibody Jackson ImmunoResearch Laboratories,  
West Grove (Pennsylvania), USA  
Goat-anti-mouse 594 antibody Jackson ImmunoResearch Laboratories,  
West Grove (Pennsylvania), USA  
Gibco goat serum Invitrogen GmbH, Darmstadt, Germany 
NeuroTrace 435 
NeuroTrace 488 
Invitrogen GmbH, Darmstadt, Germany 
Invitrogen GmbH, Darmstadt, Germany 
Anti-Proteoglycan mouse IgG1, clone 2-B-6 
antibody  
SEIKAGAKU BIOBUSINESS Company, Tokyo, 
Japan 
2.2 Tools and materials  
Microscope slides 76x26 mm Gerhard Menzel Glasbearbeitungswerk 
GmbH & Co. KG, Braunschweig, Germany 
 
Microscope cover slips  24x60 mm Gerhard Menzel Glasbearbeitungswerk 
GmbH & Co. KG, Braunschweig, Germany 
Parafilm Brand GmbH & Co. KG, Wertheim 
Germany 
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Pipettes, pipette tips and tubes (2ml and 1,5  
ml) 
Eppendorf AG, Hamburg, Germany  
12-well and 96-well cell culture plates  Becton, Dickinson and Company, Franklin 
Lakes (New Jersey), USA 
Tissue Tek Cryomold Standard, 25x20x5 mm Sakura Finetek Europe B.V. , Alphen aan den 
Rijn, The Netherlands  
Tissue Tek Cryomold Biopsy, 10x10x5 mm Sakura Finetek Europe B.V. , Alphen aan den 
Rijn, The Netherlands  
Tissue Tek optimal cutting temperature 
(O.C.T.) 
Sakura Finetek Europe B.V. , Alphen aan den 
Rijn, The Netherlands  
Vectashield Mounting Medium  Vector Laboratories, Inc., Burlingame 
(California), USA 
Paper filters (185 mm Ø circles) Whatman Schleicher & Schuell GmbH, 
Dassel, Germany 
50 ml centrifuge tubes  Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Erlenmeyer flasks (1l; 0,5 l)  Schott, Elmsford (New York), USA 
2.3. Technical devices  
Leica CM1850 cryostat Leica Microsystems GmbH, Wetzlar, 
Germany  
Vibratome 1000Plus Intracel LTD, Shepreth, Royston, 
Great Britain 
Vortex-Genie 2 Scientific Industries, Inc., Bohemia (New 
York), USA 
KERN EW 150-3M (scales)  Kern & Sohn GmbH, Balingen-Frommern, 
Germany 
Laboratory pH meter inoLAB WTW Wissenschaftlich-Technische 
Werkstätten, Weilheim, Germany  
Magnetic stirring hotplate MR 3001K and 
stirring bars 
Heidolph Instruments GmBH & Co. KG, 
Schwabach, Germany  
Ismatec IP high precision multichannel pump 
(pump for perfusions) 
ISMATEC SA, Labortechnik - Analytik, 
Glattbrugg, Switzerland 
Olympus IX71 inverted fluorescence 
microscope (evaluation of 
immunohistochemistry) 
Olympus GmbH, Hamburg, Germany 
Olympus SZX16 fluorescence 
stereomicroscope (Dissection microscope)  
Olympus GmbH, Hamburg, Germany 
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3. Imaging 
 
Olympus BX51WI upright microscope (Wide-
field epifluorescence microscope) for in vivo 
imaging equipped with x4/0.13 dry, x10/0.3 
dry and x20/0.5 dipping cone water-
immersion objectives  
Olympus GmbH, Hamburg, Germany 
Fast shutter and filer wheel Sutter Instruments, Novato (California), USA 
Height-adjustable stage with attachment for 
metal plate 
Custom-made 
Cooled SensiCam QE CCD camera The Cooke Corporation, Romulus (Michigan), 
USA 
Standard filter for fluorescent proteins Chroma Technology Corporation, Bellows 
Falls (Vermont), USA 
MetaMorph®software Molecular Devices, Orleans (California), USA 
FV1000 confocal system mounted on an 
upright BX61 microscope, equipped with an 
x10/0.4 water immersion objective and 
x20/0.85 and x60/1.42 oil immersion 
objectives (confocal microscopy) 
Olympus GmbH, Hamburg, Germany 
Custom-built multiphoton imaging setup 
based on an Olympus FV 300 scanner 
equipped with a femto-second pulsed 
Ti:Sapphire laser (Mai Tai HP, 
Newport/Spectra-Physics) 
Olympus GmbH, Hamburg, Germany 
Newport Corporation, Irvine (California), 
USA 
Olympus FV1000 MPE multiphoton 
microscope 
Olympus GmbH, Hamburg, Germany 
 
2.2 Mice 
 
In situ and in vivo experiments on central axonal regeneration were performed in Thy1-GFPs 
mice (Feng et al., 2000). In this line, the Thy1-promotor drives expression of GFP in only a 
small subset of sensory neurons, thus allowing the investigation of axonal regeneration of 
single axons. Animals were adult (between approximately six and twenty weeks of age and a 
weight of 20-30 g) and both sexes were equally distributed to both experimental and control 
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groups. For the evaluation of STAT3 expression in DRG neurons ten, twelve and fourteen 
days after viral therapy both wildtype (WT) mice on a C57/bl6 background and Thy1-GFPs 
mice were used. To delete STAT3 I used STAT3 fl/fl mice, maintained on a bl6 background 
(Takeda et al., 1998). For the nerve crush experiment we used Thy1-YFP16 mice (s. section 
4.1). Animals were kept in Eurostandard Type II long cages 365x207x140 mmH (Tecniplast, 
Hohenpreißenberg, Germany) stored in IVC rack system with a maximum of five mice per 
cage. Autoclaved food (regular food “Maus” from Ssniff, Soest, Germany) and autoclaved tap 
water were supplied ad libitum. Mice were held at a 12 h light/12 h dark cycle. Animals were 
kept at the breeding room with their parent until day twenty-one postnatal and afterwards 
weaned and separated by sex. All animal experiments were performed in accordance with 
regulations of the animal welfare act and protocols approved by the Regierung von 
Oberbayern.  
 
2.3 Methods 
 
2.3.1 Plasmid constructs 
 
The pAAV-MCS vector from Stratagene has been used to produce the viral vectors pAAV-
STAT3, pAAV-STAT3c and the control viral vectors pAAV-eCFP. For the pAAV-STAT3, the 
STAT3 gene was taken from pcDNA3 STAT3 (Adgene plasmid 8706) by excising it with the 
restriction enzymes BamHI and XhoI, whereas the STAT3c gene was cut with NotI and SwaI 
from the pRc/CMV STAT3c Flag (Addgene plasmid 8722). Then, both genes were respectively 
inserted into the pAAV-MCS at the HincII site. pAAV-eCFP was produced by excising the eCFP 
gene from the peCFP N1 plasmide at BamHI and NotI and consecutively cloning it in the 
pAAV- MCS at the HincII site. All cloning was performed by Dr. Florence Bareyre. 
 
2.3.2 Vector production and purification  
 
AAV serotype 2 particles of pAAV-STAT3, pAAV-STAT3c, pAAV-eCFP and pAAV-cre were 
produced in HEK293 cells by the adenovirus-free AAV production method (Zolotukhin et al., 
1999; Zhang et al., 2000). Genomic titers were as follows: rAAV-STAT3, 9x1012 genome 
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copies/ml; rAAV-STAT3c, 5.5x1012 genome copies/ml; rAAV-eCFP, 9.2x1012 genome 
copies/ml; rAAV-cre , 9x1012 genome copies/ml. Vector production as well as vector 
purification was performed by Joshua Sanes and In-Jung Kim (Harvard University). rAAV-cre 
was a kind donation from I.J. Kim (Harvard University). 
 
2.3.3 Tissue processing and immunohistochemistry 
 
Animals were deeply anesthetized with isofluorane and perfused transcardially with 20 ml of 
saline solution followed by 60 ml of 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer. 
Spinal cords including the injected DRGs were dissected out and tissues were post-fixed in 
4% PFA at 4 °C for 24 h. For consecutive immunofluorescence analysis, DRGs were 
transferred to 30% sucrose for at least 24 h and embedded/blocked in Tissue-Tek optimal 
cutting temperature (O.C.T.) compound. Then 20 µm thick coronal sections were cut on a 
cryostat and mounted on glass slides.   
Before immunostaining, sections were dried at room temperature (RT) for at least 2 h and 
subsequently rinsed 3 times for 10 min in TBS at room temperature. To improve antigen 
retrieval, slides were heated up to 60 °C in the microwave in Tris/EDTA followed by 15 min at 
a sub-boiling temperature. Without cooling down the slides, sections were blocked with 5% 
goat serum in 0,1% Triton X-100 in TBS for 1 h. Afterwards, sections were incubated for 1 h 
at RT and then overnight at 4 °C with either anti-STAT3 antibody (dilution 1:500) or anti-P-
STAT3 antibody (dilution 1:50) diluted in 0.1% Triton X-100-TBS and 2,5% goat serum. Slides 
were rinsed again 3 times for 10 min with 1xTBS and subsequently incubated with 
fluorescent secondary antibody (goat-anti-rabbit 594) used at a dilution of 1:500 in TBS for 2 
h. Furthermore, nuclei were counterstained using NeuroTrace 435 (dilution 1:500). For the 
STAT3 deletion experiment in the CNS (s. section 4.6) I used NeuroTrace 488. Before 
mounting the tissue in Vectashield mounting media, slides were rinsed 3 times for 10 min 
with TBS.  
In the last experiment of this study (s. section 4.7) delivery of chondroitinase ABC was 
confirmed by immunohistochemistry using the Anti-Proteoglycan mouse IgG1 (clone 2-B-6) 
antibody which recognizes 4-sulfated and 6-sulfated chondroitin and dermatan sulfates 
resulting from ChABC enzymatic digestion. Spinal cords were embedded in 2% Agarose and 
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subsequently cut in 50 µm thick sections by a vibratome. Afterwards, sections were rinsed 
for 10 min in PBS and blocked with 5% goat serum in 0,1% Triton X-100 in PBS for 1 h. Then, 
sections were incubated for 1 h at RT and then overnight at 4 °C with Anti-Proteoglycan 
mouse IgG1 (diluted in 0.1% Triton X-100-PBS and 2,5% goat serum). Sections were rinsed 3 
times for 10 minutes with PBS and subsequently incubated overnight with fluorescent 
secondary antibody (Goat-anti-mouse 594) used at a dilution of 1:500 in 0,1% Triton X-100 in 
PBS. Eventually, sections were rinsed 3 times for 10 minutes and mounted on glass slides in 
Vectashield. 
  
2.3.4 Quantification of the expression of P-STAT3 and STAT3 
 
STAT3 and P-STAT3 immunoreactivity was analyzed in DRGs of animals perfused at 10 d, 12 
d and 14 d after the injection of rAAV-STAT3 and rAAV-STAT3c into cervical DRGs (C3-C6) of 
C57/bl6 wildtype or Thy1-GFPs mice. DRG sections were stained for STAT3 and P-STAT3, 
respectively, and all sections were counterstained with NeuroTrace 435 to reveal the total 
number of neuronal nuclei in the DRG. Then, images in the red (P-STAT) and blue 
(NeuroTrace) channel of an Olympus IX71 inverted fluorescence microscope were taken and 
the proportion of DRG neurons showing STAT3 or P-STAT3 immunoreactivity was 
determined. 
 
2.3.5 Gene therapy with recombinant adeno-associated viral vectors 
 
To assess the efficiency of STAT3 gene transfer via viral vectors in C57/bl6 wildtype mice (s. 
section 0), and to determine the outcome of viral STAT3 deletion on central axon outgrowth 
in STAT3 fl/fl mice (s. section 4.6), animals were deeply anesthetized. A dorsal cervical 
laminectomy was performed on the cervical part of the spinal column (C3-C6) and the DRGs 
were surgically exposed as described in the protocol below (s. section 2.3.7.1). Then 1 µl of 
rAAV (rAAV-STAT3, rAAV-STAT3c, rAAV-cre or rAAV-eCFP) was slowly injected into the DRG 
with a glass capillary that was thinly drawn using a micropipette puller. Injections were 
performed using a stereotactic frame and a 20 ml syringe that was connected to the glass 
capillary via butterfly of a common blood collection set. All capillaries were filled by 
aspirating the virus with a 20 ml syringe before starting surgeries and kept on ice during the 
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surgical procedure. For those experiments in which the effects of axonal outgrowth after 
viral STAT3 supplementation in Thy1-GFPs were investigated (s. sections 4.4, 4.5, 4.7) in vivo 
imaging was performed prior to injection to identify suitable single fluorescently labeled 
axons with clear visible origin from a DRG. Then, selected DRGs were surgically exposed and 
injected with rAVV (s. Fig. 2-3).  
 
2.3.6 Confocal microscopy 
 
Confocal images of fixed tissue were obtained on a FV1000 confocal system mounted on an 
upright BX61 microscope (Olympus) and equipped with an x10/0.4 water immersion 
objective and x20/0.85 and x60/1.42 oil immersion objectives. Stacks of 12 bit images were 
recorded and processed using the freeware ImageJ (http://rsbweb.nih.gov/ij). 
 
2.3.7 In situ analysis of central axonal outgrowth 
 
Central branches of fluorescently labeled DRG neurons were identified in vivo and imaged 
according to the in vivo imaging protocol by the Kerschensteiner and Misgeld labs 
(Kerschensteiner et al., 2005; Misgeld et al., 2007). The protocols describes how to image 
individual fluorescently labeled axons in the spinal cord of living transgenic mice expressing 
the green fluorescent protein (GFP) in a subset of sensory neurons. The decisive steps from 
the surgical exposure of the spinal cord until the recovery of the animal are briefly outlined 
in the following.  
 
2.3.7.1 Surgical access to the dorsal surface of the spinal cord  
Before starting surgical procedures, mice were given 5 μl Metacam (analgesic) per os by a 
pipette. Then, mice were intraperitoneally anaesthetized with ketamine-xylazine (ketamine 
87 μg per g body weight, xylazine 13 μg per g body weight). Fur was clipped on the upper 
back and animals were positioned on a metal plate. Rubber bands connected to button 
magnets were used to attach all four extremities to the plate. A support pillow was put 
under the thorax to flex the vertebral column backwards and thus widen the interlaminar 
spaces (s. Fig. 2-1).  
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The skin in the surgery area was disinfected by Cutasept. Under the stereomicroscope a 
midline incision in the skin extending from the occipital bone to the upper thoracic part of 
the back was performed by a scalpel. Dorsal neck muscles were exposed and cut in the 
midline using large spring scissors. Customized magnet-mounted retractors were inserted to 
remove the muscles to the side. Sterile triangles (Sugi) were used to stop bleeding. 
Subsequently, a dorsal laminectomy was performed by removing the cervical vertebrae from 
C3 to C6 using spring scissors with angled blades. The dura was kept intact.  
 
 
Fig. 2-1 Equipment for positioning of the animal  
When the surface of the dorsal spinal cord is exposed (not shown), muscles are removed to the side by 
customized magnet-mounted retractors. A support pillow allows widening of the interlaminar space and 
rubber bands connected to button magnets attach the animal to the metal plate. Adapted from Misgeld et 
al., 2007.  
 
2.3.7.2 Imaging of fluorescently labeled axons and viral injection 
After surgical exposure of the spinal cord, Thy1-GFPs mice were transferred to the imaging 
stage consisting of an Olympus BX51WI upright microscope, a filter wheel and a cooled CCD 
camera. The low-power x4/0.13 dry objective of the microscope and fluorescent excitation 
was used to visualize GPF positive axons of the dorsal spinal cord. Single fluorescently 
labeled axons emerging from a DRG and running in the superficial dorsal spinal cord were 
identified and documented by acquiring image streams of twenty-five to fifty image (frames) 
with a cooled Sensicam QE CCD camera controlled by MetaMorph® software (s. Fig. 2-2).  
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Fig. 2-2 In vivo imaging of fluorescent sensory DRG axons in Thy-GFP
s
 mice 
                                                     Materials and Methods                                                        37 
 
 
 
Fig. 2-2 (A) In vivo microscopy setup consisting of a BX51WI upright microscope, a filter wheel and a CCD 
camera. (B) Schematic representation of the in vivo imaging of a single GFP positive DRG axon branching into 
a descending and an ascending branch. (C) Cross-section of the spinal cord of a Thy-GFP
s
 mouse. (D) Cross- 
section of a DRG of a Thy-GFP
s
 mouse stained with NeuroTrace. The arrow shows the soma of the fluorescent 
soma. (E) Black-and-white image showing an in vivo imaged single GFP-labeled DRG axon of a Thy-GFP
s
 
mouse. Scale bars in C and E 200 μm and in D 100 μm; C, D and E adapted from Kerschensteiner et al., 2005.  
 
The DRGs from which the selected axons emerged were then surgically prepared using a 
rongeur and 1 µl of the rAAVs was injected as described above (s. Fig. 2-3).  
In the experiment to determine the effect of endogenous STAT3 expression on axonal 
sprouting after a CNS lesion (s. section 4.6), STAT3fl/fl mice were used. Here, the spinal cord 
and cervical DRGs were exposed and directly afterwards injected with a combination of 1 μl 
of rAAV-cre and rAVV-eCFP. Mice serving as control animals only received rAVV-eCFP. The 
rAVV- cre encodes for a cre recombinase which recognizes the two loxP-sites flanking the 
STAT3 gene in STAT3fl/fl mice and subsequently excises STAT3. The rAVV-eCFP encodes for 
enhanced cyan fluorescent protein and allows fluorescent identification of treated axons.  
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Fig. 2-3 Injection of rAAV into the DRG  
(A) View of the surgically exposed spinal cord and injection of virus into a DRG with finely pulled glass 
capillaries. Muscles are displaced to the side by retractors. (B) Schematic representation of the injection 
process. (C) Reconstructed image from several frames acquired by in vivo imaging showing injection of a red 
fluorescent dye into a cervical DRG of a Thy-GFP
s
 mouse. Scale bars in A 2 mm and in C 500 μm. B was 
courteously provided by Fabian Laage-Gaupp.  
 
2.3.7.3 Recovery of the animal 
After having imaged the animal, dorsal neck muscles were adapted and sutured, whereas 
the skin was closed using clips. To rehydrate the animal 1 ml of Ringer’s solution was 
subcutaneously injected postoperatively. Approximately two hours after surgery as well as 
one day after surgery mice were administered 5 μl of Metacam orally.  
 
2.3.7.4 Lesion of the axon 
Ten to twelve days after the DRG injection the dorsal surface of the spinal cord was 
surgically re-exposed and the previously selected fluorescent axon was re-identified under 
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the widefield microscope and transected using a hand-held 23-gauge hypodermic needle. 
The lesioned axon end was then documented in vivo (s. Fig. 2-4).  
In the experiment of STAT3 deletion (s. section 4.6), viral application of rAVV-eCFP resulted 
in fluorescent labeling of axons, thus allowing identification of treated axons with a high 
probability. Ten days after injection, the spinal cord was re-exposed. Fluorescently labeled 
axons were identified under the fluorescent microscope and lesioned by a small diameter 
needle (s. above).  
 
 
Fig. 2-4 Lesion of the axon emerging from a DRG previously injected with rAAV 
(A) Schematic representation of the lesion process with a hand-held small diameter needle. (B) Black-and-
white image showing a frame of an in vivo imaged single GFP-labeled DRG axon of a Thy-GFP
s
 mouse directly 
after lesion with a small diameter needle (asterix).  Scale bar in B 200 μm. Image B modified from 
Kerschensteiner, et al. 2005. 
 
2.3.7.5 Evaluation of the axonal outgrowth after lesion 
To determine the frequency of axonal sprouting after rAAV-treatment, the animal was 
perfused transcardially with 4% PFA two days after the lesion and the previously imaged 
segment of the spinal cord was dissected (s. Fig. 2-5). At first, the spinal cord was imaged in 
situ mounting it in a customized imaging chamber consisting of a glass slide with a well of 
parafilm. The transected axon was documented using high resolution confocal microscopy as 
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described above. Then, some spinal cords were afterwards embedded in 2% Agarose and 
subsequently cut in 100 – 250 µm thick sections by a vibratome. The sections were mounted 
in Vectashield and re-imaged again to achieve better imaging quality. Confocal image stacks 
were processed as described above and the transected axons were reconstructed from the 
DRG root to the lesion site.  
 
 
Fig. 2-5 Dissected spinal cord  
Dissected spinal cord put on millimeter paper. The black arrow points to the injected DRG (blue dot). The 
inset shows the DRG and the root of the spinal nerve at a higher magnification. The photo was courteously 
provided by Fabian Laage-Gaupp. 
 
Two blinded observers evaluated the axons by classifying their terminal ends as either 
“sprouts” or “bulbs” based on their characteristic morphological appearance. Furthermore, 
the number of collateral sprouts emerging from the transected axons was counted. In the 
experiment where I combined rAAV-STAT3 therapy and application of chondroitinase ABC 
                                                     Materials and Methods                                                        41 
 
 
 
the lengths of axonal sprouts was measured. Axonal terminals ending in tips or bulbs were 
classified as non-growing axons and their outgrowth was set to 0 μm.  
2.3.8 In vivo analysis of central axonal outgrowth 
 
To determine the speed of axonal outgrowth after STAT3 supplementation in Thy1-GFPs 
mice, transected axons were re-imaged in vivo at day 2 and 4 after lesion. For these 
purposes, a custom-build multi-photon imaging setup based on an Olympus FV 300 scanner 
equipped with a femto-second pulsed Ti:Sapphire laser (Mai Tai HP, Newport/Spectra-
Physics) was used. Image stacks of 50 - 200 images per stack (spaced at 1 μm in z) were 
acquired for each frame with a 20x dipping cone water-immersion objective. During the 
imaging session the spinal cord was superfused with aCSF. After in vivo imaging at day 2 and 
day 4, animals recovered and at day 10 they were perfused transcardially with 4% PFA. The 
previously imaged part of the spinal cord was dissected out, the transected axons were re-
identified in the fixed tissue and imaging of the axons in the intact spinal cord using an 
Olympus FV1000 MPE multiphoton microscope was performed. Image stacks of 20 - 100 
frames were acquired with a 25x objective. Imaging stacks were processed using ImageJ 
software. Frames containing the axon in focus were selected and the transected axons were 
reconstructed using Photoshop. To determine the growth of the transected axon ends the 
distance from the axon end to a characteristic proximal structure (in most cases the Y-
branch point in the dorsal root, in some cases a crossing point with another axon) at two, 
four and ten days after lesion was measured. To compensate for tissue changes due to 
fixation in the perfused samples, a “constant” distance e.g. between two branch points in 
the same unlesioned axon both in vivo and in the corresponding fixed tissue was measured 
to determine a sample-specific “correction factor”. The length of the transected axon end 
measured in fixed tissue was then multiplied by this correction factor.  
 
2.3.9 Combination therapy with viral gene transfer and chondroitinase 
ABC  
 
Ten days following injection of either rAVV-STAT3 or rAVV-cre (control) into cervical DRGs of 
Thy1-GFPs mice, the axons were lesioned and a first bolus of either 5 μl chondroitinase ABC 
(10 U/mL in saline with 0,01% BSA) or vehicle only (saline with 0,01% BSA) were 
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administered with a pipette to the lesion on the surface of the spinal cord. Directly after 
lesion, an osmotic minipump filled with either chondroitinase ABC or vehicle only (control 
animals) was connected to the brain infusion kit. The latter one was inserted into the lateral 
ventricle and the pump was positioned between cervical muscles and skin. The pumps then 
started delivering 0,5 μl/h of either chondroitinase ABC or saline for seven days. Ten days 
after lesion, animals were perfused with PFA, the spinal cords were imaged in situ by 
confocal microscopy (s. above) and the outgrowth was evaluated as described above. To 
confirm delivery of chondroitinase ABC, spinal cords were embedded in 2% Agarose and 
subsequently cut in 100 – 250 µm thick vibratome sections. Then, free floating 
immunohistochemistry using then Anti-Proteoglycan mouse IgG1 (clone 2-B-6) antibody was 
performed as described above. In addition, loaded pumps were weighed before 
implantation and the weight was compared to the weight the pumps had at the end of the 
experiment to confirm delivery.  
 
2.3.10 Statistical analysis 
 
Results are given as mean ± SEM unless indicated otherwise. Statistical significance was 
determined using GraphPad Prism (GraphPad Software). All data were analyzed using either 
a one-way ANOVA followed by a Tukey post-hoc test for multiple comparisons or a t-test for 
single comparisons. To evaluate the proportion of terminal sprouts after rAAV treatment, a 
frequency analysis was made using a Chi square test. Significance levels were chosen as 
follows: * = p<0.05; ** = p<0.01 *** = p<0.001. 
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3 Experiments in the Course of this Study prior to my own 
Work 
___________________________________________________________________________ 
First experiments of this study defining the role of STAT3 for axonal regeneration in the PNS 
were performed by Dr. Florence Bareyre. As the results of these investigations marked the 
starting point of my own subsequent research, the main findings are briefly outlined in the 
following. 
STAT3 depletion impairs the regeneration of PNS axons 
First, it could be demonstrated that after bilateral saphenous nerve lesion, STAT3 expression 
was highly upregulated already one hour after injury until two weeks after transection. 
Second, selective deletion of STAT3 in DRG neurons of STAT3fl/fl mice by adeno-associated 
viral delivery of cre recombinase impaired regeneration of lesioned peripheral axons: At day 
4, STAT3-deficient mice showed impaired regeneration compared to STAT3-competent 
axons. However, at day 14, sprouting and axonal regeneration was comparable between 
both groups, indicating that STAT3-deficient axons could still initiate axonal outgrowth, 
however, with a delay.  
STAT3 deletion impairs initiation but not perpetuation of PNS axon 
regeneration in vivo 
To then define if impaired regeneration of STAT3-deficient peripheral axons was due to a) 
delayed growth induction or b) to reduced elongation of regenerating axons, axonal 
outgrowth was observed by repetitive in vivo imaging. Whereas many STAT3-competent 
DRG axons initiated growth within two days after lesion and progressed with an average 
speed of 132 ± 23 μm/day from day 2 to day 3, the vast majority of STAT-3 deficient axons 
failed to initiate growth during that time. Their regeneration speed was only 33 ± 6 μm/day. 
However, during the phase of axon elongation at seven to eight days after lesion, there was 
no difference between the regeneration speed of the two groups (411 ± 48 μm/day in 
STAT3-competent axons versus 341 ± 53 μm/day in STAT3-deficient axons). This indicated 
that STAT3 is crucial for initiation but not for elongation of axonal regeneration.  
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4 Results 
___________________________________________________________________________ 
4.1 Consequences of a peripheral crush lesion on STAT3 expression 
 
As described in the previous section (s. section 3), it could be shown that STAT3 expression is 
significantly upregulated after a peripheral nerve cut lesion. Moreover, it could be 
demonstrated that STAT3 is crucial for the induction of axonal outgrowth but not for 
subsequent elongation of PNS axons. These results not only suggest that the neuronal 
growth response to the lesion is divided into at least two different phases but also allow the 
hypothesis that components of the neuronal environment, such as Schwann cells forming 
the nerve sheath might influence the distinct phases of axonal regeneration. To address this 
question, saphenous nerve crush lesions (performed by Dr. Florence Bareyre) that do not 
interrupt Schwann cell nerve sheaths were performed in Thy1-YFP16 mice. Wallerian 
degeneration of crushed nerves was observed resulting in approximately 85% of axonal loss 
distal to the lesion indicating that most axons were interrupted by the crush lesion. I 
consecutively examined the DRGs that corresponded to the crushed nerves for STAT3 
activation by immunohistochemistry at different time points after lesion (s. Fig. 4-1). 
The results show that STAT3 is not significantly upregulated at any of the time points. At 
maximum, two days after lesion 30 ± 3% of DRG neurons are positive for P-STAT3. These 
results suggest that if Schwann cell guidance is maintained STAT3 is not needed for initiation 
of axonal regeneration.  
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Fig. 4-1 Wallerian degeneration and STAT3 expression after peripheral nerve crush lesion 
(A) Confocal image showing Wallerian degeneration of axons in the distal stump of a saphenous nerve four 
days following saphenous nerve crush (indicated by asterisk) in Thy1-YFP
16
 mice. The areas boxed in A show 
intact axons rostral to the lesion (B) and axonal fragments distal to the lesion (C) at a higher magnification. 
(D) Quantification of the loss of continuous axons distal to the lesion at four days after injury. (E-G) Confocal 
images show STAT3 activation in an unlesioned control DRG (E), in a DRG four days following saphenous 
nerve cut (F) and in a DRG four days following saphenous nerve crush (G). (H) Quantification of the number 
of P-STAT3–positive DRG neurons (which were identified by NeuroTrace counterstaining at different time 
points following saphenous nerve crush). n = 5-8 DRGs for each time point. Scale bars in A 400 μm, in B 40 
μm and in E 100 μm. Figure modified from Bareyre, Garzorz et al., 2011.  
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4.2 STAT3 expression after dorsal column lesion 
 
As previously outlined, a lesion of the peripheral branches of DRG neurons is followed by 
successful regeneration as well as significant upregulation of STAT3 activation. To first 
determine if there is a correlation between the weak growth response of neurons after a 
lesion of their central projections and endogenous STAT3 levels, the expression of 
phosphorylated STAT3 in DRG neurons was detected at one hour, six hours, two days, one 
week and 2 weeks after bilateral dorsal column transection. It could be found that P-STAT3 
immunoreactivity in DRG neurons after lesion of the central branch did not show significant 
changes from STAT3 activation in unlesioned control animals: Baseline STAT3 activation, 
represented by the percentage of P-STAT3 positive neurons in uninjured animals was 15 ± 
3% (s. Fig. 4-2, Fig. 4-3). In mice having undergone bilateral column lesion 29 ± 6% of 
neurons were P-STAT3 positive after one hour of injury and only 12 ± 3% of neurons were P-
STAT3 positive two days after injury. These findings contrast strongly with those in the PNS, 
where a lesion of the saphenous nerve leads to sustained STAT3 activation in more than 70% 
of L3 DRG neurons.  
 
 
Fig. 4-2 STAT3 expression after dorsal column lesion  
Quantification of the number of P-STAT3 positive neurons identified by NeuroTrace at different time points 
following dorsal column lesion in WT mice and in control WT mice. n = 6 DRGs per time point.  
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Fig. 4-3 STAT3 expression after dorsal column lesion (Immunohistochemistry)  
Confocal images of cervical DRGs immunostained for P-STAT3 (red) and counterstained with NeuroTrace 435 
in Wt unlesioned control mice (A) and in Wt mice one hour (B) and two days (C) after dorsal column lesion 
(DCL). (D) In comparison P-STAT3 expression in L3 DRGs of Wt mice after saphenous nerve cut lesion (SNC) 
two days after injury. Scale bar in A 100 µm. Figure modified from Bareyre, Garzorz et al., 2011. 
 
4.3 Efficiency of the viral gene therapy 
 
To determine whether activation of STAT3 in DRGs is sufficient to induce central axonal 
regeneration I first assessed if STAT3 expression could exogenously be increased by viral 
gene therapy. Thus, rAAVs were produced expressing STAT3 (rAAV-STAT3) or a constitutively 
active variant of STAT3 (rAAV-STAT3c) and the efficiency of the viral gene transfer was 
investigated by injection of the viruses into cervical DRGs of adult C57/bl6 WT mice. STAT3 
activation was then assessed for three time points (ten, twelve and fourteen days after 
injection) by immunohistochemistry with anti-STAT3 and anti-P-STAT3-antibodies on 
cryostat-cut DRG sections (s. Fig. 4-4). To rule out that virus injection might itself trigger an 
increase of endogenous STAT3 levels, I injected rAAV-eCFP as control viruses. Quantification 
of STAT3 activation in DRGs injected with control viruses was performed in context of the 
following experiment (s. section 4.4).  
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Fig. 4-4 Evaluation of the efficiency of the viral gene therapy by immunohistochemistry 
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Fig. 4-4: rAAV-STAT3 and rAAV-STAT3c are effective tools to deliver STAT3 to cervical DRG neurons. Images 
taken with the Olympus IX71 inverted fluorescence microscope illustrating STAT3 and P-STAT3 
immunoreactivity at ten days (A,D,G,J), twelve days (B,E,H,K,N,O) and fourteen days (C,F,I,L) after injection of 
rAAV-STAT3 (A-F), rAAV-STAT3c (G-L) or rAVV-eCFP as conrol virus (M-O). To quantify the percentage of 
STAT-3 positive neurons, neurons were identified by NeuroTrace 435 counterstaining (A-L, N and O). In 
contrast to rAAV-STAT3 and rAAV-STAT3c, rAAV-eCFP treatment is not resulting in increased levels of STAT3 
activation. Scale bars in A-O 100 µm. 
 
On average 80% of DRG neurons are transduced by rAAV-STAT3 and rAAV-STAT3c which can 
result in high levels of P-STAT3 expression at all three time points analyzed (s. Fig. 4-5).  
 
 
Fig. 4-5 Quantification of the Efficiency of the viral gene therapy)  
On average 80% of DRG neurons show STAT3 (A) and P-STAT3 (B) expression ten, twelve and fourteen days 
after injection of rAAV-STAT3 and rAAV-STAT3c which shows that rAAV are effective tools to deliver STAT3 to 
cervical DRG neurons. n = 3-5 DRGs per group and time point.  
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Interestingly, both STAT3c and STAT3 expression led to a similar percentage of P-STAT3 
positive neurons. Transduction with rAAV-STAT3 is thus sufficient to induce cytoplasmatic 
STAT3 expression as well as its phosphorylation and translocation to the nucleus. The finding 
that overexpressed STAT3 is readily phosphorylated and transported into the nucleus 
suggests that at least in this case STAT3 activation is regulated on the expression and not on 
the phosphorylation level. In conclusion, STAT3 expression can be successfully substituted by 
viral gene therapy and viral gene transfer is thus a suitable tool to investigate the effects of 
STAT3 overexpression on axonal outgrowth in the following experiments. 
 
4.4 Effects of viral gene therapy with STAT3(c) on axon outgrowth 
after CNS lesion 
 
For the investigation of central axonal regeneration Thy1-GFPs mice were used. In these 
animals the green fluorescent protein is expressed stochastically in only a small subset of 
neurons allowing imaging of individual central projections from cervical DRG neurons. To 
examine the effect of STAT3 gene therapy on the outgrowth of lesioned central DRG 
branches, I identified suitably labeled central branches of DRG neurons in the dorsal 
funiculus of the cervical spinal cord and injected rAAV either expressing STAT3 (rAAV-STAT3), 
a constitutively active form of STAT3 (rAAV-STAT3c) or a control protein (eCFP or cre 
recombinase) into the corresponding DRGs. Efficiency of viral gene transfer was confirmed 
by immunohistochemistry (s. Fig. 4-6).   
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Fig. 4-6 Effects of viral gene therapy on CNS outgrowth  
Confocal images of cervical DRGs immunostained for P-STAT3 and counterstained with fluorescent 
NeuroTrace 435 in lesioned Thy1-GFP mice injected with control rAVV (A), rAAV-STAT3 (B) or rAVV-STAT3c 
(C). Insets: Higher magnification (x3) of the GFP positive neurons boxed in the images. (D) Quantification of 
the number of P-STAT3 positive DRG neurons in mice previously injected with either control rAAV (grey 
column), rAAV-STAT3 (pink column) or rAAV-STAT3c (red column) at two days after a central lesion. n = 6 
animals per group. Scale bar in A 100 µm. Figure modified from Bareyre, Garzorz et al., 2011.  
 
Ten to twelve days after the injection of the virus, the spinal cord was surgically re-exposed, 
and the axons emerging from the injected DRGs were re-identified and selectively lesioned 
with a small-diameter needle. Two days after lesion, the axons were re-imaged ex vivo by 
high–resolution confocal microscopy and their endings were classified as „bulbs“ (non-
growing axons) or „sprouts“ (growing axons). The time course of this experiment is shown in 
Fig. 4-7 and the results of the experiment in Fig. 4-8 and Fig. 4-9.  
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Fig. 4-7 Time course of the experiment 
Ten to twelve days after injection of the virus, the axons were lesioned and the regenerative response was 
imaged 2 days after lesion. 
 
As expected, two days after lesion only 8% of axons emerging from DRGs injected with 
control rAAV have formed sprouts (Fig. 4-8 A and B; Fig. 4-9 A). In contrast, 50% of the axons 
emerging from DRGs injected with rAAV-STAT3 (Fig. 4-8 C and D; Fig. 4-9 B) and 54% of the 
axons emerging from DRGs injected with rAAV-STAT3c (Fig. 4-8 E and F; Fig. 4-9 C) showed 
an early growth response. Another interesting finding is that STAT3 expression not only 
increased terminal sprouting, but also collateral sprouting along the axon. When testing viral 
efficiency in WT mice (s. section 0) it could be found that STAT3c and STAT3 overexpression 
led to a similar percentage of P-STAT3 immunoreactivity suggesting that substitution of 
STAT3 alone is sufficient to induce its phosphorylation and transport to the nucleus. In line 
with this finding, the similar growth responses of DRG neurons injected with rAAV-STAT3 
and rAAV-STAT3c furthermore suggest that overexpression of STAT3 alone is not only 
sufficient to induce its phosphorylation and import to the nucleus but also its down-stream 
effects on regeneration. 
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Fig. 4-8 Effects of viral gene therapy on CNS outgrowth – confocal microscopy 
Confocal images of lesioned central branches derived from DRGs injected with control rAAV (A, B), rAVV-
STAT3 (C, D) or STAT3c (E, F). B, D and F: Higher magnification of axonal endings boxed in A, C and E. Boxed 
collateral sprouts are shown at higher magnification x2 in additional insets (C, E). Quantification of terminal 
(G) and collateral (H) sprouting of rAAV-STAT3, rAVV-STAT3c and control rAAV transduced central DRG 
branches two 2 days after transection. Scale bars: E 100 µm, F 25µm. Figure modified from Bareyre, Garzorz 
et al., 2011. 
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Fig. 4-9 Gallery of axonal endings 
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Fig. 4-9: Representative selection of axon endings two days after lesion. Axons emerged from DRG neurons 
that were injected with either control rAAV (A), rAAV-STAT3 (B) or r-AAV-STAT3c (C). Axonal sprouts 
(asterisks) are rarely found in control axons but are frequent in axons emerging from DRG neurons 
expressing STAT3 or STAT3c. Scale bar in A 25 μm. Figure modified from Bareyre, Garzorz et al., 2011. 
 
4.5 The phase-specific role of STAT3 for axon regeneration in the 
CNS 
 
The previous experiment revealed that overexpression of STAT3 increased the growth 
response in a substantial fraction of transected central DRG neurons. However, in line with 
the investigations in the PNS where STAT3 has turned out to initiate but not perpetuate axon 
regeneration, I wanted to determine if overexpression of STAT3 affected different phases of 
axon outgrowth. To show the growth pattern of individual axons in the same animal at 
distinct time points I used repetitive in vivo and ex vivo imaging (s. Fig. 4-10 ) 
 
 
Fig. 4-10 Timecourse of the experiment 
Ten to twelve days after injection, axons were lesioned and in vivo imaged at two and four days after lesion. 
Ten days after lesion the axon was imaged ex vivo.  
 
To determine if STAT3 can not only initiate but also perpetuate axonal outgrowth, DRGs of 
Thy1-GPFs mice were either injected with control rAAV, rAAV-STAT3 or rAVV-STAT3c. As 
described above axons emerging from the injected DRG were re-identified and lesioned ten 
to twelve days after gene therapy. Two and four days after lesion, the spinal cord was 
surgically re-accessed and the selected axon was re-imaged by in vivo multi-photon 
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microscopy. After lesion at D10, animals were perfused and the axons were imaged by ex 
vivo multi-photon microscopy. Axonal lengths at each time point were measured and the 
speed of growth between D2 and D4 after lesion as well as between D4 and D10 was 
measured. 
I could show that viral STAT3 treatment increases the speed of axonal growth in the early 
phase (two to four days) of regeneration (33 ± 8 µm/day in rAAV STAT3 axons and 36 ± 17 
µm in rAAV STAT3c transduced axons vs. 7 ± 2 µm/day in control axons; Fig. 4-11 A,B and C). 
However, this early growth cannot be sustained and only limited axonal extension can be 
observed in all three groups between D4 and D10 after lesion (1,2 ± 0,7µm/day in rAAV-
STAT3 transduced axons and 10 ± 8 µm in rAVV-STAT3c transduced axons vs. 1 ± 0,5 µm/day 
in control axons, Fig. 4-11 A, B and D). In line with what has been shown in the PNS, STAT3 
controls the initiation but not the elongation of axonal outgrowth. 
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Fig. 4-11 Phase specific role of STAT3 for axonal regeneration 
Multiphoton images of the lesioned DRG axons emerging from DRGs injected with control rAAV (A) or rAVV-
STAT3 (B) imaged at two, four and ten days after lesion. Insets show magnification of axon ends. (C and D) 
Quantification of axonal growth speed in vivo between D2 and D4 (C) and between D4 and D10 (D) after 
injection of control rAAV (grey bars), rAVV-STAT3 (red bars) or rAVV-STAT3c (orange bars). Scale bar in B 200 
μm. Figure modified from Bareyre, Garzorz et al., 2011. 
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4.6 Effects of STAT3 deletion on axonal outgrowth after CNS lesion 
 
In the PNS, STAT3-deficient axons show minimal sprouting and extension during the initial 
phase of regeneration compared to STAT3-competent neurons. However, at later time 
points, sprouting around the lesion site and the speed of axonal regeneration between 
STAT3-deficient and STAT-3 competent axons is comparable. This suggests that after a lag 
phase other regulators can initiate regeneration. To investigate if STAT3 deficiency would 
influence sprouting in the same way it does in the PNS, STAT3 was deleted in cervical DRG 
neurons of STAT3fl/fl mice (Takeda et al., 1998). In these mice, STAT3 is flanked by two loxP-
sites that can be recognized by a cre recombinase which subsequently deletes STAT3 (s. Fig. 
4-12).  
 
 
Fig. 4-12 Schematic illustration of STAT3 deletion in STAT3 
fl/fl
 mice via cre recombinase   
Schematic illustration of the cre/loxP system (Kuhn et al., 1997) used in this experiment to specifically delete 
STAT3 in DRG neurons. The cre recombinase recognizes the two loxP sites flanking the STAT3 gene and 
subsequently excises the sequence coding for STAT3. In control animals where the cre recombinase is absent, 
the STAT3 gene stays in the genome.  
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DRGs were injected with 1 μl of rAAV-eCFP (control animals) or rAAV-eCFP and rAVV-cre 
(experimental animals) encoding for cre recombinase. Ten days after viral application the 
eCFP fluorescently labeled axons were identified under the fluorescent widefield microscope 
and lesioned by a small diameter needle. Two days after injection, animals were perfused 
and axonal sprouting was evaluated. Immunohistochemisty on control and experimental 
animals was performed to determine the level of STAT3 activation after viral treatment. As 
expected, in animals receiving the combination of rAAV-eCFP and rAAV-cre, the percentage 
of P-STAT3 positive DRG neurons was significantly reduced compared to those who received 
eCFP only (23 ± 4% in STAT3-competent DRGs vs. 8 ± 2% in STAT3-depleted DRGs).  
I found that the anyhow low baseline sprouting of CNS neurons is not influenced by STAT3 
deletion: 15% of axons emerging from STAT3-deficient DRGs show sprouts compared to 12% 
sprouts in STAT-3 competent axons (s. Fig. 4-13). This might suggest that in analogy to the 
findings in the PNS, additional factors can initiate axonal outgrowth independent of STAT3. 
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Fig. 4-13 Sprouting response of STAT3-competent and STAT3-depleted DRG neurons after a CNS lesion and 
evaluation of P-STAT3 immunoreactivity in the corresponding DRGs.  
A) Quantification of the number of terminal sprouts in STAT3-competent DRGs (treated with rAAV-eCFP only) 
and STAT3-deficient DRGs (treated with rAAV-cre and rAAV-eCFP) showing that STAT3 deletion does not 
influence the sprouting response at baseline. (B) Quantification of P-STAT3 immunoreactivity in STAT3-
competent and STAT3-deficient DRGs verifies successful deletion of STAT3 in STAT3 
fl/fl
 mice via cre 
recombinase. (C, D) Confocal images illustrating P-STAT3 immunoreactivity in control DRGs (C) and in STAT3 
depleted DRGs (D).  Scale bar in C 200 µm.  
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4.7 Combination therapy with rAAV-STAT3 and chondroitinase ABC 
for central axon regeneration 
 
In the PNS (s. section 3), as well as in the CNS (s. section 4.4), it could be shown that STAT3 
successfully initiates axonal outgrowth but does not support elongation of growing axons at 
later time points. To determine if axonal growth at later time points could be improved by 
additional treatment regimens, the induction of STAT3 by viral gene transfer of rAAV-STAT3 
was combined with the application of chondroitinase ABC, an enzyme neutralizing inhibitory 
scar components (Silver et al., 2004). Ten days after injection of rAVV-STAT3 or control rAVV, 
axons emerging from the injected DRGs were lesioned, 5 μl of chondroitinase ABC (chABC) 
was locally applied to the lesion site and an intrathecal pumps delivering either 
chondroitinase ABC or saline into the cerebrospinal fluid were installed (Installation of 
pumps was performed by Dr. Claudia Lang). Ten days after lesion of the axon, the outgrowth 
in the four groups (STAT3 + chondroitinase ABC, STAT3 alone, chondroitinase ABC+ control 
rAAV and control rAVV alone) was analyzed ex vivo by confocal imaging (s. Fig. 4-14). 
Immunohistochemistry analysis on spinal cords treated with ChABC (or saline as control) 
subsequently confirmed successful delivery of ChABC to the spinal cord (s. Fig. 4-15). 
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Fig. 4-14 Confocal images of axonal outgrowth after combination therapy with rAAV-STAT3 and 
chondroitinase ABC 
Confocal images illustrating central axonal outgrowth ten days after lesion of DRG axons treated with rAVV-
STAT3 plus saline (A), rAAV-cre plus saline (C), rAAV-STAT3 plus chondroitinase ABC (D) and rAAV-cre plus 
chondroitinase ABC (F). (B and E) Higher magnification view of axonal sprouts boxed in A and D. The yellow 
lines indicate the lesion site. Scale bars in A, C, D and F 100 μm; Scale bars in B and E 25 μm. 
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Fig. 4-15 Immunohistochemistry on spinal cords confirming delivery of chondroitinase ABC  
Confocal images of spinal cords treated intrathecally with chondroitinase ABC (A) or saline as control (B). Spinal 
cords were immunostained for 4-sulfated and 6-sulfated chondroitin and dermatan sulfates resulting from 
ChABC enzymatic digestion with the Proteoglycan mouse IgG1 clone 2-B-6. Scale bar in A  200 μm.  
 
I found that axonal outgrowth was increased by more than twofold in axons treated with 
rAAV-STAT3 + chondroitinase ABC (141 ± 53 μm) compared to those treated with rAVV-
STAT3 and saline (42 ± 26 µm) and those treated with rAAV-cre and saline (30 ± 18 μm). 
Axons treated with chondroitinase ABC + rAVV-cre showed axonal outgrowth of 64 ± 28 μm, 
suggesting improved growth compared to the rAAV-cre + saline group and the rAAV-STAT3 + 
saline group. This trend as well as the trend of improved outgrowth in axons treated with 
rAAV-STAT3 + condroitinase ABC compared to those treated with chondroitinase ABC plus 
rAVV-cre or rAVV-STAT3 alone, were, however, not statistically significant (Fig. 4-16).  
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Fig. 4-16 Combination therapy with rAAV-STAT3 and chondroitinase ABC 
Central axonal outgrowth ten days after lesion of DRG axons treated with rAAV-STAT3 plus chondroitinase 
ABC (red bar), rAAV-STAT3 plus saline (light red bar), control rAVV plus chondroitinase ABC (dark grey bar) 
and control rAVV plus saline (light grey bar).  
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5 Discussion 
___________________________________________________________________________ 
5.1 STAT3 is a key component of the intrinsic growth program 
 
STAT3, as shown in this study, can initiate early stages of axon growth: In the PNS, its 
deletion leads to impairment of axonal regeneration by affecting the timely initiation of 
outgrowth. In the CNS, overexpression enables axonal sprouting of transected axons even in 
the hostile CNS environment. The finding that modulating the expression of a single 
intracellular molecule can change the growth response of a neuron highlights the 
importance of intrinsic mediators of axonal outgrowth. In the past, most research has been 
focused on the extrinsic growth inhibitory signals; however, several lines of arguments 
indicate that the intrinsic growth properties of neurons are equally important determinants 
of axon regeneration. 
First, therapies only targeting the CNS environment have not yet been shown to sufficiently 
allow the majority of axons to regenerate for long distances and allow functional recovery: 
For example, there are studies on two of the most intensively investigated therapies, namely 
chondroitinase ABC – digesting inhibitory CSPGs in the extracellular CNS matrix – and Nogo-
A antibody – targeting inhibitory Nogo-A in CNS myelin, that demonstrate the limitations of 
the two approaches in terms of successful regeneration (Bartsch et al., 1995; Davies et al., 
1997; Davies et al., 1999; Lemons et al., 2003; Zheng et al., 2003; Silver et al., 2004; Yiu et al., 
2006; Lee et al., 2009; Tom et al., 2009).  
Second, when talking about “extrinsic therapies”, it needs to be clarified that intrinsic and 
extrinsic pathways do not work independently of each other as neuronal cells are firmly 
embedded in a nonneuronal environment. Due to this neuronal-nonneuronal cell interaction 
it is very likely that a variety of inhibitory extrinsic signals from different sources eventually 
converge on similar neuronal pathways. In this context, identifying common intracellular 
pathways in neurons might open new perspectives in the field of axonal regeneration. 
Ideally, we would be able to kill many birds with one stone by targeting one or few single 
common downstream mediators. For example, two of the extrinsic key inhibitors, Nogo-A 
and CSPGs have been shown to bind to neuronal receptors and consecutively turn on the 
cytoplasmatic RhoA/ROCK pathway. After activating this signaling cascade, the cytoskeleton 
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is rearranged and the growth cone collapses (Filbin 2003; Yiu et al., 2006; Bradbury et al., 
2011; Tan et al., 2011). Interestingly, a recent review elucidated the close relationship 
between STAT3 and the Rho family of small GTPases including RhoA by showing that Stat3 is 
activated by Rac1, Cdc42 and RhoA (Raptis et al., 2011). It remains speculative at this point 
to deduce that both Nogo-A and chondroitinase ABC as key inhibitors in myelin and scar 
eventually alter STAT3 expression via RhoA/ROCK signaling in neurons.  
Third, as the neuronal intrinsic growth program has attracted increasing scientific interest, a 
couple of promising molecular pathways and some of their components have recently been 
identified (s. introduction). Among these are cAMP and its downstream mediators (Qiu et al., 
2002; Deng et al., 2009), a couple of transcription factors (Moore et al., 2011), the growth 
cone-associated proteins GAP-43 and CAP-23 (Bomze et al., 2001) and members of the 
PTEN/mTOR pathway (Park et al., 2008; Liu et al., 2010). The results of our study have 
identified STAT3 as an important mediator of axonal growth initiation and future research 
needs to determine how STAT3 interacts with the other intrinsic components found to play 
an important role for axonal regeneration. As eventually signals related to regeneration end 
up activating transcription factors to alter gene expression, a better understanding of the 
intrinsic neuronal growth program – especially of the transcription factors and their various 
interactions will – be required. Thus, as mentioned above, many extrinsic and intrinsic 
factors could be once bundled and allow only targeting some few, pivotal downstream 
mediators.  
 
5.2 STAT3 is an initiator of neurite outgrowth in vivo 
 
Previous studies have already suggested a role of STAT3 for axonal regeneration. It could be 
demonstrated that increased levels of STAT3 expression and phorsphorylation are 
associated with axonal regeneration in the PNS (Schwaiger et al., 2000; Sheu 2000; Xia et al., 
2002). Moreover, molecules activating STAT3 such as IL-6, CNTF and intracellular inhibitors 
of STAT3 such as SOCS3 can influence axonal regeneration (Zhong et al., 1999; Cafferty et al., 
2001; Qiu et al., 2005; Smith et al., 2009) and most recently, Smith and colleagues revealed 
that STAT3 expression promotes neurite outgrowth in cultured cerebellar granule neurons 
(Smith et al., 2011).  
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In this study, we could demonstrate for the first time that STAT3 expression is not only 
associated with regeneration but essential for the timely induction of axon outgrowth in 
vivo. STAT3 deletion in lumbar DRG neurons led to impaired sprouting and fewer and shorter 
regeneration of the lesioned saphenous nerve fibers compared to STAT3-competent neurons 
four days after lesion. Two weeks after lesion, regeneration speed between STAT3- 
competent and STAT3-deficient axons reached similar levels. However, – due to the delay of 
initiating regeneration in the STAT3-deficient group – long-distance regeneration of STAT3-
deficient axons was still impaired, while many STAT3-competent axons have already re- 
entered the distal stump.  
In the CNS, I found similar effects of STAT3: Two days after lesion, approximately half of the 
axons emerging from DRGs that had undergone STAT3 and STAT3c gene therapy formed 
sprouts after lesion. In contrast, the number of sprouts in control axons was fourfold lower, 
indicating that the failure of CNS axons to start growing is directly associated with the failure 
of neurons to upregulate STAT3 expression when their central neurites are lesioned. These 
findings corroborate very well the study of Qiu and colleagues suggesting that STAT3 
expression is involved in the conditioning lesion paradigm (Qiu et al., 2005). This paradigm 
characterizes the phenomenon that a peripheral lesion of DRG neurons one to two weeks 
prior to a dorsal column lesion can condition the neuron and leads to extensive outgrowth 
after a subsequent lesion of its central branch (Neumann et al., 1999; Hoffman 2010). A 
peripheral injury can “prime” the DRG neurons by increasing their intrinsic growth capacity 
enabling subsequent regeneration of lesioned central branches. The term “conditioning 
lesion” indicates that mature neurons can be reprogrammed to enhance growth capacity in 
both a permissive and a restrictive extracellular environment. Thus, it suggests that there is a 
common intrinsic neuronal growth program that is in principle able to initiate both PNS and 
CNS outgrowth but which is, however, only induced after a PNS lesion.  
The underlying molecular mechanisms of this phenomenon are only partly understood; 
however, it could be clearly demonstrated that gene transcription is crucial for the neurons’ 
regenerative ability (Smith et al., 1997). In line with this, Qiu and colleagues could 
demonstrate that perineural infusion of JAK2 inhibitor AG490 which blocks phosphorylation 
of STAT3 significantly reduces dorsal column axonal regeneration in the adult spinal cord 
after a pre-conditioning sciatic nerve transection. As in our study we could show that a) a 
peripheral lesions upregulates STAT3 expression and b) overexpression of STAT3 is sufficient 
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to induce sprouting of CNS axons, the following can be concluded: A peripheral lesion – 
where STAT3 is persistently upregulated - mimics the effect of STAT3 supplementation and 
thus ascribes STAT3 a pivotal role for the underlying mechanisms of the effect of 
conditioning lesions.   
However, it also needs to be mentioned at that point that STAT3 is not the only factor which 
is in the position to initiate neuronal outgrowth of lesioned axons. We could show, that in 
the PNS, STAT3-deficient axons can still start a growth response, indicating that 
compensatory mechanisms can, albeit a delay of several days, initiate the neuronal growth 
program when STAT3 is not available. In the CNS, a comparable phenomenon can be seen: 
When STAT3 is deleted in DRG neurons, the baseline sprouting of central branches is 
comparable to that of STAT3-competent neurons suggesting that additional factors seem to 
induce CNS outgrowth in the absence of STAT3. One can assume that other transcription 
factors might help out and act as “second line” troop, when the “first line” growth starter 
STAT3 is not available. Especially the fact that the growth-associated transcription factors 
strongly co-operate backs up this hypothesis. The following selection of findings exemplifies 
this complex interaction: In vivo knockdown of Sox11 reduces expression of ATF-3 
(Jankowski et al., 2009). ATF-3 has been shown to activate c-Jun and form functional 
heterodimers with c-Jun and CREB. Moreover, it is assumed that ATF3 may as well interact 
with STAT3 (Seijffers et al., 2007). In the context of pancreatic cancer, CREB has been 
demonstrated to enhance IL-6 transcription which in turn activates STAT3 (Zhang et al., 
2010). C-Jun and STAT3 interact to co-operate in transcriptional activities (Zhang et al., 1999) 
and STAT3 and Smad1 form complexes that are involved in the fetal brain development 
(Nakashima et al., 1999).  
Considering the close interaction of transcription factors, a question of particular interest 
arises: What are the (common) downstream mechanisms that mediate the effects of STAT3 
and of possible “second line” transcription factors, for example which common genes are 
induced or repressed? 
Answering this question will provide us with a better understanding of the molecular 
machinery that initiates axonal growth and thus help us developing more specific 
therapeutic interventions. As STAT3 is a transcription factor and thus, downstream effects 
are mediated by altering gene expression, the focus lies on identifying neuroprotective and 
pro-neuroregenerative genes that are directly upregulated by STAT3. Among the genes that 
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were found to be induced by STAT3, the bcl-2 family turned out to play a critical role in this 
context. Bcl-2 and bcl-xL were demonstrated to be crucial for neuron survival after injury 
and protection of neurons from toxic insults (Merry et al., 1997). Reg-2, another survival 
gene, and bcl-xL were found to be less upregulated in STAT3 conditional knockouts after 
nerve lesion (Schweizer et al., 2002). Furthermore, other anti-apoptotic genes such as 
survivin may be involved in axonal regeneration. STAT3 induces survivin gene expression 
(Gritsko et al., 2006) and a recent study demonstrated that survivin is gradually upregulated 
in the distal and proximal parts of the sciatic nerve after injury (Amiri et al., 2009).  
Apart from these molecules, other downstream targets have become identified as pro-
regenerative: STAT3 is closely linked with growth-associated protein 43 (GAP-43), as 
blockade of STAT3 phosphorylation leads to reduced levels of GAP-43 resulting in 
compromised neurite outgrowth (Qiu et al., 2005). SPRR1A, a regeneration-associated 
protein, is activated upon IL-6 and gp130 signaling as well as by transcription factor Sox11 
(Pradervand et al., 2004; Jing et al., 2012). SPRR1A is induced by more than sixtyfold after 
peripheral axonal damage and its overexpression augments axonal outgrowth in vitro 
(Bonilla et al., 2002). Also, the cell cycle inhibitor p21/Cip1/Wafl is directly targeted by STAT3 
and contributes to neurite outgrowth by inhibiting the Rho kinase activity (Coqueret et al., 
2000; Tanaka et al., 2002). More recently, a transcriptional profiling study has identified a 
particularly interesting gene target of STAT3, the interferon regulatory factor 1 (IRF1). 
Overexpression of this transcription factor enhanced neurite outgrowth in cultured 
cerebellar neurons to a similar extend as overexpression of STAT3 itself (Smith et al., 2011).  
 
In my study, I could demonstrate that the amount of sprouting axons in animals treated with 
rAAV-STAT3 is comparable to those treated with rAAV-STAT3c. Immunohistochemistry 
showing approximately the same percentage of P-STAT positive neurons after gene therapy 
with both rAAV-STAT3 and rAAV-STAT3c supports this observation. In contrast to STAT3, 
STAT3c dimerizes spontaneously and independently of prior phosphorylation by JAKs. 
Therefore, one could presume that STAT3c should have stronger and more prolonged effects 
on axonal outgrowth than STAT3. However, overexpression of STAT3 alone turned out to be 
sufficient to induce its phosphorylation and import to the nucleus. This might indicate that 
STAT3 action – at least in DRG neurons – is primarily regulated at the expression and not at 
the phosphorylation level.  
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Smith and colleagues (Smith et al., 2011), however, only detected significant neurite 
outgrowth in cells transfected with STAT3c and not STAT3. Also the first paper describing the 
generation of STAT3c conclusively showed that STAT3c is indeed more effective than STAT3 
(Bromberg et al., 1999): Though STAT3c dimerizes spontaneously, even more STAT3c-dimers 
formed under additional stimulation of tyrosine phosphorylation by tyrosine kinases (which 
is the case when STAT3c is transferred to a normally functioning cell). Moreover, the DNA 
binding activity in STAT3c transformed cells was higher than the one in cell lines where 
endogenous STAT3 was constitutively activated by v-src (a tyrosine kinase) that had been 
transferred to the cell.   
My findings might differ from the results of Smith and Bromberg, as I used adeno-associated 
viruses in living animals instead of cells in culture which were transfected with plasmids. In 
my model, DRG neurons were embedded in a real environment of glial cells and fibroblasts. 
Upon injection of rAAV, most likely an inflammatory milieu was created attracting immune 
cells that together with the local tissue released cytokines such as IL-6 (Akira et al., 1992) . 
These in turn might have strongly and continuously activated the JAK/STAT pathway which 
maintained the phosphorylation of STAT3 molecules provided by viral gene therapy. In line 
with this, a maximal saturation of STAT3 phosphorylated molecules could be achieved in 
both rAAV-STAT3c and rAAV-STAT3 transduced cells. As cells in culture which are solely 
transfected with plasmids are neither exposed to stimuli of other cell populations nor to 
inflammatory processes as triggered by rAAV-STAT3(c), one can assume that in these cells 
STAT3, but not STAT3c underlies the various downregulating mechanisms (s. introduction).  
As outlined, my results are in favor of a model proclaiming that an optimal level of activated 
STAT3 can be achieved in both rAAV-STAT3 and rAAV-STAT3c-transduced cells. Smith’s and 
Bromberg’s results - not taken into account that the results from their cell culture 
experiments are not directly comparable to my in vivo work- rather argue for a model in 
which STAT3c is more effective than STAT3.   
Considering both models when evaluating the results of my experiments, one might suggest 
that whenever a certain (unknown) optimal level of activated STAT3 is reached, an additional 
increase of STAT3 activity does not further improve axonal outgrowth. In line with this 
hypothesis we found that overexpression of either STAT3 or STAT3c by viral gene transfer 
did not further improve PNS regeneration indicating that a PNS lesion alone is sufficient to 
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induce optimal STAT3 levels or in other words: A PNS lesion is sufficient to induce the 
optimal level of activated STAT3 which is needed to drive the regenerative response.  
 
5.3 STAT3 is a phase-specific regulator of axonal regeneration  
 
To clearly show how STAT3 would affect different phases of axonal outgrowth in the CNS we 
used an in vivo imaging approach. Traditionally, research on axonal regeneration has been 
performed studying fixed tissue in which axons were stained by tracing techniques or 
immunohistochemistry. However, these methods are limited as regeneration can only be 
assessed after having sacrificed the animal. Thus, it’s not possible to evaluate the dynamics 
of the regenerative process during at least more than one distinct time point. Also, it is 
difficult to distinguish regenerated axons from those that were never lesioned as well as 
from collateral sprouting of undamaged fibers (Steward et al., 2003; Misgeld et al., 2006). In 
vivo microscopy, however, allows the investigation of single cells in the living animal 
(Misgeld et al., 2006). By visualizing individual fluorescent axons repeatedly, I could directly 
assess the effect of rAAV-STAT3(c) treatment in individual axons over time and thus, gain 
direct insights into the growth dynamics which I might not have gained by other methods.  
In this project, in vivo imaging revealed that STAT3 deletion in lumbar DRG neurons impaired 
the regeneration of saphenous nerve fibers in the PNS at both four and fourteen days after 
injury. However, at day 14, sprouting around the lesion and regeneration at short distances 
from the proximal stump were not significantly different between STAT3-deficient and 
STAT3-competent axons and at twenty-eight days after lesion, similar amounts of STAT3-
competent and STAT3-deficient axons have re-approached their targets.  
This indicates that STAT3-deficient axons can still start the regeneration process. Subsequent 
repetitive in vivo imaging then disclosed that impaired regeneration of STAT3-deficient 
axons is not due to reduced elongation but due to delayed growth induction: The speed of 
axon growth during the early phase (two to three days following injury) of regeneration is 
significantly reduced in STAT3-deficient mice compared to STAT3-competent mice. However, 
in the later phase (seven to eight days after injury) of the regeneration process, the speed of 
growth does not differ between the two groups. In the CNS, repetitive in vivo multiphoton 
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imaging showed a similar pattern: STAT3 and STAT3c overexpression increased the speed of 
axonal growth in the early phase (two to four days after lesion) of regeneration more than 
threefold compared to control axons. At late (4-10 days after lesion) time points, however, 
the growth speeds did not differ between the control and the STAT3(c)-treated groups. 
Taken together, these results identified STAT3 as a phase-specific regulator of neuronal 
outgrowth. STAT3 is needed for the timely initiation of the growth program after lesion. But 
once these processes have been implemented, STAT3 is not longer required for the 
perpetuation of axonal regeneration. Thus, there is evidence that the growth response in 
vivo is divided into at least two distinct phases, initiation and elongation, that are probably 
regulated by distinct molecular mechanisms.  
The idea of a multi-phasic growth program has previously been proposed based on research 
in Aplysia californica. Studying the reaction upon nerve injury in Aplysia, a model was 
suggested that proposed several temporally distinct phases (Ambron et al., 1996): Phase 1 is 
characterized by injury induced action potentials acting via calcium and cAMP. In phase 2 
MAP kinases are activated and retrogradely transported to the nucleus. Phase 3 is 
characterized by signals from the environment such as growth factors and cytokines. All 
phases eventually lead to alteration of gene expression. The last phase then stops growth by 
inhibitory target-derived factors. 
In the concept of a multi-phasic growth regulation, the transcription STAT3 contributes to 
regeneration in the early phase likely by inducing a variety of genes such as IRF1 and SPRR1A 
(s. above). In line with the early action of STAT3, we could detect increased P-STAT3 levels 
already at one hour after saphenous nerve cut that started to decrease slowly after two 
weeks, indicating that STAT3 is rapidly activated after peripheral injury. Subsequent 
investigations should now aim to identify factors involved in the elongation phase. The 
results of Sheu and colleagues might already provide evidence for a candidate regulator of 
axonal elongation: After peripheral nerve transection, they found that Erk phosphorylation 
persisted longer than STAT3 phosphorylation and was, in contrast to STAT3, also intense at 
the distal nerve stump. They concluded that Erk and its downstream mediators are crucial 
for establishing and maintaining an ideal extracellular environment in the distal nerve stump 
for axons growing towards them (Sheu 2000).  
More generally, the idea of a phase-specific regeneration program suggests that 
environmental cues are decisive for shaping the distinct phases of axonal regeneration. In 
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the PNS, the switch from growth initiation to elongation could be initiated by the interaction 
of Schwann cells with growing axons. As previously described, Schwann cells form the 
“bands of Büngner” guiding axons to their targets (Hoke 2006). The role of STAT3 in this 
context could be to induce neurite outgrowth before contacts with Schwann cells are 
established. Once a re-growing axon has contacted a Schwann cell, the cellular program 
shifts to the elongation mode and no longer requires STAT3. The idea that axonal growth 
along glial support structures does not require STAT3 can be corroborated by our results 
from the peripheral crush lesion: After a peripheral crush lesion which does not interrupt 
Schwann cell guidance, STAT3 is not activated. Obviously, crush and cut lesions implicate 
different injury signals and cellular responses that need to be further elucidated.  
In the CNS, changes in the environmental circumstances might as well explain the transition 
between the different growth phases, namely the switch from the at least partially 
successful initiation of axonal outgrowth to the failure of axonal elongation: In the CNS, 
there are no Schwann cells that support regenerating axons after the first growth initiation. 
In contrast, STAT3-transduced axons attempting to grow encounter a hostile CNS 
environment containing myelin inhibitors that becomes even more growth repelling when 
the glial scar develops. These changes in the lesion environment could explain why 
overexpression of STAT3 can only initiate early growth but fails to support it later. In line 
with this idea, combination of viral STAT3 treatment together with chondroitinase ABC 
increased the length of axonal outgrowth. STAT3 can thus “jump-start” the intrinsic growth 
capacity and prime axons for therapies such as chondroitinase ABC that can sustain 
elongation.   
 
5.4 STAT3 is a promising target for therapeutic interventions 
 
My project identifies STAT3 as a potent initiator of axonal outgrowth. Hence, STAT3 might 
become an interesting candidate to use – either alone or in combination with other reagents 
– for therapeutic interventions that aim to promote central axonal regeneration. To be once 
able to make the step from “bench to bedside”, a couple of questions and problems need to 
be addressed:  
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1. When is the optimal timeframe after spinal cord injury to start therapy with STAT3 
and is there a “too late” from a therapeutical point of view? 
2. Should we directly target STAT3 or rather its upstream or downstream mediators? 
What component of the JAK/STAT might be therapeutically interesting? 
3. How can we manage to induce STAT3 in a way that is both targeted to neurons and 
well tolerated by the receiving organism?  
 
5.4.1 Being in the right place at the right time 
 
In this study, rAAV-STAT3 and rAAV-STAT3c were injected ten to twelve days prior to the 
lesion allowing sufficient upregulation of STAT3 before the injury was set. However, this 
application scheme is clearly not feasible for spinal cord injured patients. Future clinical 
application of STAT3 would only become a realistic goal if proven that growth can also be 
induced when it is applied immediately after the injury or – to offer therapy to patients with 
chronic SCI – even when it is applied at a later time point.  
So far there is no direct data for STAT3 itself, however, there is strong evidence from the 
conditioning lesion paradigm: A recent study demonstrated that DRG neurons that were 
conditioned after lesion of the central branch initiate an intrinsic growth program with 
upregulation of RAGs that is similar to neurons conditioned before CNS injury. Moreover, 
significant central axonal regeneration was observed in these “post-conditioned axons”. 
This, however, occurred only in the absence of growth-repelling traumatic tissue which is the 
case when single axonal lesions were performed by minimal tissue traumatic two-photon 
laser injury (Ylera et al., 2009). Another study in which different therapeutical approaches 
were combined was tested one year after spinal cord injury and came to similar results: 
Grafts of marrow stromal cells together with NT-3 application and a peripheral nerve 
conditioning lesion allow axon regeneration bridging the lesion site. The gene profile seen in 
the post-conditioned neurons remarkably resembles the one in pre-conditioned neurons 
(Kadoya et al., 2009). A recent study comparing the efficacy of peripheral sciatic nerve crush 
lesions to cAMP elevations on central sensory axonal regeneration could amongst others 
demonstrate that regenerative effects persisted whether conditioning lesions were applied 
prior to or shortly after spinal cord injury (Blesch et al., 2012) 
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As STAT3 induction has been shown to mimic the effect of a conditioning lesion, there is 
hope that pro-regenerative effects of STAT3 can also be detected when STAT3 is delivered 
post injury. However, it needs to be considered that the more time passes after injury the 
more likely a strong hostile environment will develop and very likely undo STAT3 effects. In 
particular for later time points, a combination with reagents mitigating the extracellular 
matrix such as Nogo-A-antibody or chondroitinase ABC will be needed (s. below).  
 
5.4.2 In search of the ideal target in the JAK/STAT pathway 
 
5.4.2.1 Upstream and downstream player in the JAK/STAT pathway and their potential 
for therapy 
STAT3 has been turned out to be a potent initiator of neurite outgrowth. However, as STAT3 
is a pleiotropic mediator embedded in a complex signaling cascade, it might also induce 
unwanted side effects (s. below). Thus, the question arises if in the long run it would be also 
possible to target other mediators downstream or upstream of STAT3 that are either more 
convenient to target or safer when applied to patients. 
In this context, the neuropoietic cytokine IL-6 that can activate the JAK/STAT pathway 
(Schindler et al., 1995) has emerged as an interesting candidate: Hiruta and colleagues found 
accelerated regeneration of lesioned peripheral nerves in transgenic mice constitutively 
expressing both IL-6 and IL-6 receptor (Hirota et al., 1996). In line with this, sensory 
impairments and delayed regeneration of peripheral sensory axons in interleukin-6-deficient 
mice was found (Zhong et al., 1999). Eventually, the pro-regenerative role of IL-6 could be 
also shown in the CNS in the context of traumatic brain injury (Swartz et al., 2001). A recent 
study showed that intrathecal delivery of IL-6 after cortical spinal tract injury in rats 
promoted regeneration and functional recovery by inducing the expression of growth-
associated genes (Yang et al., 2012). In contrast to STAT3, IL-6 could be easily delivered by 
direct intrathecal application which would be of great advantage. However, there is evidence 
that more upstream interventions apart from promoting growth simultaneously induce 
effects abrogating the growth effect by activating different cell populations and signaling 
pathways. The first in vivo study to show the effect on IL-6 after SCI revealed that IL-6 as an 
upstream mediator of the JAK/STAT impaired axonal regeneration (Lacroix et al., 2002). In 
accordance with this, blocking the IL-6 receptor was shown to ameliorate functional 
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recovery in spinal cord injury (Okada et al., 2004; Mukaino et al., 2010). These negative 
results are not extremely surprising as IL-6 is a strong pro-inflammatory cytokine and 
activates in vivo many cell populations around the lesion side which in turn create an 
overwhelming pro-inflammatory response hindering successful regeneration.   
Thus, more downstream interventions in the STAT3 cascade might allow more precise 
targeting of pro-regenerative genes. Pleiotropic effects of upstream players such as IL-6 
leading to activation of genes not being involved in axonal outgrowth or – in the worst case 
– even induce cell harming effects could be avoided. It’s also interesting to note that even 
STAT3 itself does not only upregulate pro-regenerative genes but also genes encoding for 
proteins such as SOCS3 which are negative regulators of the JAK/STAT pathway (Croker et 
al., 2008; Sun et al., 2010). 
So far, the genetic alterations upon STAT3 activation that promote axonal regeneration are 
not sufficiently examined. The future will show if genes targeted by STAT3 such as IRF1 and 
SPRR1a (s. above) will have the potential to be considered as target molecules for axonal 
regeneration. Also deletion of negative regulators of the JAK/STAT pathway may be 
interesting approaches (Smith et al., 2009; Sun et al., 2011). 
 
5.4.2.2 Harnessing the pleiotropic effects of STAT3 for therapy 
As described above, using activators of STAT3 for therapy might result in pleiotropic effects. 
Also focusing on genes activated by STAT3 might narrow down the therapeutic effect as the 
entire set of genes responsible for the growth-promoting effect of STAT3 are not yet 
defined. Thus, as of now, STAT3 itself should be considered as a target of clinical endeavors. 
In this context, however, it is important to note that the effects of STAT3 are not only 
confined to neuronal cells. The role of STAT3 for inflammation and cancer has been well-
documented and is of high clinical significance. Also there is evidence that STAT3 is involved 
in astrogliosis and scar formation after injury. The following paragraphs give an overview of 
the nonneuronal effects of STAT3 that help understanding why a possible STAT3 therapy 
needs to be target-oriented and carefully designed. 
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5.4.2.2.1 Effects of STAT3 on glial cells 
Very rapidly upon spinal cord injury, reactive astrocytes migrate to the lesion and set up a 
dense barrier around the injury side, the glial scar. The function of reactive astrocytes after 
spinal cord injury is largely dependent on STAT3 signaling (Okada et al., 2006). Though it 
could be shown that STAT3 activation in glial cells after SCI is necessary to organize the scar, 
preventing unorganized inflammation and consecutively reducing functional deficits (Okada 
et al., 2006; Herrmann et al., 2008), it remains unclear if STAT3 activation in astrocytes is 
also beneficial during chronic phases. Especially if using STAT3 therapy over a long time to 
promote neuronal outgrowth it could – when applied in a non-selective way – in the same 
time continue activating astrocytes that will in particular during later phases impair axonal 
regeneration as a physical and chemical barrier.  
 
5.4.2.2.2 Effects of STAT3 on inflammation and cancer 
First discovered as an acute-phase response factor (Akira et al., 1994) and activated by pro-
inflammatory molecules such as IL-6, STAT3 has been shown to be closely linked with pro- 
inflammatory processes (Alonzi et al., 2001; Kisseleva et al., 2002; Pfitzner et al., 2004; 
Adamson et al., 2009; Aggarwal et al., 2009).  
More importantly, STAT3 is crucial for tumorigenesis and - to build the bridge to its role in 
inflammation – involved in inflammation-induced cancer, as has been shown for 
Helicobacter pylori associated gastric cancer (Yu et al., 2009). Apart from extrinsic signals 
such as bacteria and chemical agents, also intrinsic factors such as overexpression of growth 
factor receptors and oncogenic mutations in JAKs can lead to constitutive activation of 
STAT3 and thus to tumorigenesis (s. below). As previously described, constitutively activated 
STAT3 has been found in many tumor entities such as breast cancer, prostate cancer and 
melanoma (Bromberg 2002). Eventually, cancer related effects of STAT3 are carried out on 
the transcription level: tumor “survival gene products” - which are in the same time pro-
regenerative genes in axonal regeneration - such as bcl-xl, bcl-2, survivin, Mcl-1 and cIAP2 
are upregulated and lead to suppression of apoptosis (Yu et al., 2009). These tumor 
promoting properties would clearly restrict the use of STAT3 as therapeutic agent in the 
treatment of SCI.  
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At this point, however, it needs to be emphasized that STAT3 per se is not an oncogene. It 
has to be categorized as proto-oncogene fulfilling completely physiological functions within 
the cell: The first study to directly demonstrate the intrinsic oncogenic potential of STAT3 
was performed in 1999, when Bromberg and colleagues created a constitutively active 
variant of STAT3, the STAT3c, that was capable of transforming fibroblasts resulting in 
subsequent tumor formation (Bromberg et al., 1999). In the STAT3c molecule, two cysteine 
residues are substituted within the C-terminal loop in the SH2 domain, allowing the 
molecule to spontaneously dimerize by disulfide bonds without requiring tyrosine 
phosphorylation. However, there is so far no evidence of naturally occurring mutations 
transforming STAT3 molecules into constitutively active variants. In naturally occurring 
tumors, constitutive STAT3 activation depends on dysregulated processes within the 
JAK/STAT signaling pathways such as overexpression of receptors and cytokines, 
methylation-induced silencing of the SOCS1-gene as found in hepatocellular carcinomas 
(Bromberg 2002) and mediators (e.g. IL6) activated by STAT3 itself that create a feed-
forward loop eventually activating STAT3 (Yu et al., 2009). Of great clinical importance is the 
vast range of JAK mutant myeloproliferative neoplasms including Polycythemia vera and 
essential thrombocytosis (Stein et al., 2011). 
In my project, I injected rAAV-STAT3 as well as rAAV-STAT3c to neuronal cells. As described 
above, the two different STAT3 viruses showed a similar effect on axonal regeneration. This 
indicates that the constitutive, oncogenic form is not necessary for therapeutic success 
which makes a clinical application less risky. Furthermore, I investigated STAT3 levels on 
rAAV-STAT3 injected DRGs of mice that had been perfused approximately three months 
after viral injection. Preliminary data showed, that STAT3 level declined to baseline 
indicating that at this late time point cell-intrinsic mechanisms are turned on to silence 
STAT3 expression. The therapeutic success is thereby not hindered, as STAT3 exerts its effect 
exclusively during initiation of growth. However, as STAT3 is involved in a broad palette of 
nonneuronal cell activities that are only partly understood, selective neuronal targeting of 
therapeutic STAT3 induction might be necessary.  
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5.4.3 Bringing STAT3 to neuronal cells: Maximal efficacy and minimal side 
effects 
 
The two main methodical approaches to manipulate STAT3 expression are gene therapy as 
used in our study and pharmacological approaches. Until today, latter ones would not be 
able to directly transport STAT3 into the cells but they could target upstream mediators in 
the JAK/STAT pathway that activate STAT3 such as IL-6. Though IL-6, e.g., can be well 
delivered intrathecally (Yang et al., 2012), it would imply an intolerable risk due to its strong 
pro-inflammatory properties that are able to produce an overwhelming inflammatory milieu 
endangering a patient with SCI (s. above). As summarized above, therapy would need to be 
selective to neurons and the most efficient method in this context would be gene therapy. 
Successful gene therapy is mainly dependent on powerful methods to express genes of 
interest into target cells. Particularly efficient tools in this context are viruses representing a 
natural vector for delivery and expression of exogenous genes. Among the many different 
virus families, adeno-associated viruses (AAV) have become increasingly popular as they are 
apathogenic, available in many serotypes that allow tissue-specific targeting, stable in their 
host organism over time and modest concerning the immune response they elicit (Daya et 
al., 2008). Also, recombinant AAV (rAVV) vectors have the tendency to rather stay in 
episomal form than integrating into the host genome which reduces the risk of insertional 
mutagenesis (Nakai et al., 2001). As rAAV have also been successfully transferred into 
neurons (Xiao et al., 1997; Glatzel et al., 2000), we used rAAV for our STAT3 gene therapy. In 
line with others we could yield a high transfection rate of DRG neurons: On average 80% of 
DRG neurons show P-STAT3 expression ten, twelve and fourteen days after injection of 
rAAV-STAT3, respectively rAAV-STAT3c. 
It’s thus not surprising that currently more than 80 trials are performed using AAV as vectors 
(source: http://www.abedia.com/wiley/vectors.php). To name just a few examples of 
successful clinical trials with AAV: Kaplitt and colleagues could show that injection of AAV 
carrying a transgene encoding glutamatic acid decarboxylase (GAD) into the subthalamic 
nucleus of patients with Parkinson’s disease was not only safe and well tolerated by patients 
but also led to clinical improvement. Another trial investigated the effect of gene therapy 
with AAV in patients suffering from Leber’s congenital amaurosis (LCA), a group of inherited 
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blinding diseases. All patients treated with AVV injected subretinally showed evidence of 
improvement of retinal function (Maguire et al., 2008; Maguire et al., 2009). 
However, there are also obstacles in AAV therapy that need to be overcome. Very 
importantly, it could be shown that transgene-expressing cells are eliminated by the 
adaptive and innate immune system (Mingozzi et al., 2011; Rogers et al., 2011). In the first 
clinical trial in which AAV were introduced into the liver of hemophilia B patients to transfer 
human blood coagulation factor IX, two subjects developed transient elevation of liver 
enzymes, indicating destruction of hepatocytes most likely mediated by AAV capsid-specific 
CD8(+) T-cells (Manno et al., 2006). Even when adding an immunosuppressive regimen to 
dampen immunologic processes there was no improvement in AAV5-based liver gene 
transfer in non-human primates (Unzu et al., 2012). In the previously described study on 
congenital amaurosis, the therapeutic success might be not least due to the fact that the eye 
is an immunoprivileged organ. In contrast, after acute spinal cord injury, there is a strong 
inflammatory response recruiting a variety of immune cells (Bareyre et al., 2003). Especially 
in this milieu, AAV therapy could be in danger of being counteracted by a strong immune 
response which in the worst case would eliminate transduced neuronal cells.  
But there is hope, that in the future, AAVs can be engineered to overcome the reactions of 
the immune system. For example, there have been efforts to increase the transduction 
efficiency of vector particles by changing the capsid structure. This enables a fewer amount 
of AAV to achieve the same expression levels as higher titers of wild-type AAV (Li et al., 
2010; Bartel et al., 2011). Others pre-treated mice with glucocorticoids before delivering 
adenoviral vectors and could demonstrate that innate toxicity is ablated (Seregin et al., 
2009). As corticosteroids are anyhow applied in SCI, a possible combination therapy with 
rAAV-STAT3 and corticosteroids raises hopes that rAAV-STAT3 can once be transferred to 
spinal cords in humans.  
 
5.5 STAT3 in combination with other therapeutic targets  
 
As described in previous chapters, various mechanisms including inflammation, the absence 
of permissive molecular and cellular bridging, myelin and extracellular matrix inhibitors, 
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reduced neurotrophic stimulation and an insufficient induction of the intrinsic neuronal 
growth program avoid successful regeneration after spinal cord injury. Thus, combination 
therapies that target more than one parameter seem to promise greater potency in eliciting 
regeneration than single therapies. Lately, several studies confirmed this hypothesis: 
Combination of stimulating intrinsic responses by cAMP application with a growth 
permissive gradient of NT-3 has been shown to promote axonal regeneration beyond spinal 
cord injury sites (Lu et al., 2004). Similarly, combination of cAMP with Schwann cells grafts 
promotes axonal growth and functional recovery after spinal cord injury (Pearse et al., 
2004). Other studies combined chondroitinase ABC with cell therapy (Fouad et al., 2005), 
peripheral nerve grafts (Houle et al., 2006) and growth factors (Massey et al., 2008), 
respectively, and found improved axonal regeneration and functional recovery. Sun and 
colleagues double deleted two components of the intrinsic growth program, namely SOCS3 
inhibiting the STAT3 pathway and PTEN (s. introduction), resulting in sustained axonal 
regeneration of the optic nerve compared to a single deletion of either the one or the other 
factor. (Sun et al., 2011). In a recent study, an electrochemical neuroprosthesis consisting of 
epidural electrical stimulation as well as a mixture of serotonin and dopamine receptor 
agonists was applied in rats after hemisection of the spinal cord. The research group could 
demonstrate that a robotic postural interface forcing the rats to actively use their paralyzed 
hindlimbs during electrochemically favorable states as created by the neuroprosthesis could 
remodel spared neuronal circuitries and regain supraspinal control of locomotion (van den 
Brand et al., 2012). 
 
In this project, I investigated STAT3 in combination with chondroitinase ABC and 
demonstrated that average axonal outgrowth over ten days after lesion was increased more 
than twofold in animals treated with both chondroitinase ABC and rAAV-STAT3 compared to 
animals treated with rAAV-STAT3 alone or chondroitinase ABC alone or control animals. 
Though my results were only significant for the group of animals treated with rAAV-STAT3 
plus chondroitinase ABC compared to the group of control animals (saline plus rAAV-cre), 
there is a clear trend towards increased axon regeneration when therapies are combined 
compared to single therapy approaches. The fact that rAAV-STAT3 treatment alone e.g. did 
not result in significantly better regeneration than treatment with rAAV-cre alone highlights 
the fact that STAT3 only induces outgrowth, but during later time points, when axons get 
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into contact with the increasingly hostile environment of the CNS, they stop regenerating. 
The results of my combination experiment are consistent with a previous study, in which 
functional regeneration of central DRG branches through the dorsal root entry zone in the 
spinal cord was improved by combining chondroitinase ABC with a pre-conditioning 
peripheral lesion (Steinmetz et al., 2005). Interestingly, the similarity between the results 
from this study and the ones from my combination therapy with chondroitinase ABC and 
rAVV-STAT3, suggest that indeed STAT3 overexpression can mimic the effect of a peripheral 
conditioning lesion.  
Furthermore, the improved outcome of combined application of STAT3 and chondroitinase 
ABC compared to single therapy with rAAV-STAT3 alone or chondroitinase ABC alone, 
respectively, demonstrates that outcome can be improved when targeting both extrinsic and 
intrinsic factors. The need for combining different strategies can be figuratively compared to 
driving a car: Taking one’s foot off the brake is not enough to drive a car. One also needs to 
step on the accelerator (Steeves et al., 1998). In this study, we identified STAT3 as a key 
intrinsic regulator of axonal outgrowth, thus representing the accelerator. However, as 
shown by multiphoton imaging in this project, the initial growth cannot be sustained 
between four and ten days after lesion. However, when chondroitinase ABC is applied in 
addition, axons can elongate further in the hostile CNS environment. In this way, 
chondroitinase ABC releases the brakes and paves the way for growing axons. Although 
CSPGs are already upregulated within twenty-four hours after injury and hence suggesting 
that they might prevent axon regeneration across acutely forming scar tissue, the highest 
peaks of CSPGs and thus inhibition are detected at later time points ranging between eight 
and fourteen days (Jones et al., 2003; Tang et al., 2003). Therefore, chondroitinase ABC 
might amplify STAT3 effects in the early induction phase of growth, but more significantly, 
support elongation at later stages. This shows as well that in terms of combination 
treatment, one would ideally think of components that also target the moleculary distinct 
phases during axonal growth (s. above). 
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5.6 Concluding remarks and outlook 
 
In my thesis I could identify STAT3 as a potent initiator of axonal outgrowth in the CNS. 
Overexpression of STAT3 in DRG neurons significantly increased sprouting of the central 
branches after lesion, thus successfully mimicking the effect of a pre-conditioning peripheral 
lesion. Moreover, repetitive imaging of fluorescently labeled axons in living animals enabled 
me to directly observe the phase-specific action of the therapeutic intervention on the 
regeneration process in vivo: For the first time, I could show that STAT3 supplementation 
was sufficient to induce axonal growth but unable to sustain it during later periods. Together 
with similar findings in the PNS, it can be suggested that the intrinsic growth response can be 
at least divided into two distinct phases of regeneration, namely initiation and elongation. 
Latter one is most probably shaped by environmental cues, such as myelin proteins and scar 
in the CNS, that stall outgrowing axons. In line with this theory, combination of STAT3 with 
intrathecal delivery of chondroitinase ABC that neutralizes inhibitory scar components 
increased the length of growing axons. 
The insights gained in this study add an important puzzle piece to the understanding of the 
complex intrinsic growth program. As it becomes more and more obvious that extrinsic 
approaches in enhancing regeneration are not sufficient alone and – interestingly, might 
even converge in part on similar intracellular pathways, scientific efforts have nowadays 
been increasingly focused on elucidating the intrinsic mechanisms that control neuronal 
growth. Many components of intracellular signaling have been found to drive axonal 
regeneration and further investigations are now needed to determine how these different 
factors act in temporal and spatial concert to develop target-specific therapies with maximal 
outcome and minimal side effects.  
Currently, a number of therapies targeting different mechanisms in the pathology of spinal 
cord injury are being developed and some have even been applied to humans (s. Tab. 1-1). 
However, none of these therapies has so far led to groundbreaking success. It becomes more 
and more clear that the disappointing results in humans might be attributed to differences 
in species as well as to the experimental designs which do not match realistic clinical 
situations of SCI (Dietz 2010). For example, whereas in animals application of olfactory 
ensheathing cells (OEC) promoted long-distance axonal regeneration in the transected adult 
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rat spinal cord (Ramon-Cueto et al., 1998), human trials with OEC have only shown little to 
no effect (Mackay-Sim et al., 2011). Thus, it’s not surprising that especially results from cell 
culture experiments - which are even more insufficient in mimicking the complex processes 
in human SCI - cannot necessarily be translated to humans. In addition, it needs to be taken 
into account that even if there is successful axon regeneration, there is not automatically 
function improvement. In particular non-directional growth can even lead to aberrant 
regeneration causing pain, paresthesia and other unwanted effects (Thoenen et al., 2002).  
That’s why in recent years not only axon regeneration but also axon reorganization has been 
in the focus of spinal cord injury research. As spinal cord injuries rarely present as complete 
lesions, improving reorganization of the spared fibers might help to establish functional 
bypasses and promoting functional remodeling of existing circuits. The most successful 
therapies in rodents namely chondroitinase ABC and Nogo-A antibody have been shown to 
not only positively influence regeneration but also reorganization. There is even evidence 
that inhibitors of myelin rather remodel existing circuits than promote long-distance 
regeneration (Bareyre et al., 2004; Silver et al., 2004). 
In humans, marked improvements of functional recovery could be mainly achieved by 
improving reorganization. Especially locomotor training which facilitates stepping 
movements of the legs using body weight support on a treadmill to provide appropriate 
sensory cues has been shown to improve walking (Harkema 2001; Dietz et al., 2004). When 
combined with electrical stimulation of the spinal cord, a 23-year-old patient with paraplegia 
was even able to elicit full weight-bearing standing and to voluntarily execute some motor 
functions (Harkema et al., 2011). This provides an interesting parallel to a recent rodent 
study in which a cocktail of excitatory agents was applied in combination with electrical 
stimulation and training. In doing so, voluntary control of locomotion could be restored (van 
den Brand et al., 2012).  
In my study, I could demonstrate that STAT3 supplementation did not only increase terminal 
sprouting. In addition, significant numbers of collaterals formed along the lesioned axons, 
indicating that STAT3 might also positively influence reorganization. Recent research in our 
lab could eventually prove that overexpression of STAT3 via viral gene therapy not only 
improved regeneration of lesioned CST axons but also positively influenced reorganization of 
neuronal connections after unilateral CST lesion. STAT3 triggered the formation of new 
collaterals emerging from the unlesioned side and both behavioral and electrophysiological 
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assessments displayed that new intraspinal circuits formed, thus contributing to functional 
recovery (Lang et al., submitted).  
In summary, these findings indicate that STAT3 is not only a key initiator of axonal 
regeneration but can also support the reorganization of spared neuronal circuits after spinal 
cord injury. The pro-regenerative properties of STAT3 and its ability to increase 
reorganization might – combined with training to integrate regenerating and intact fibers 
into functional neuronal circuits –  in the future help to improve functional recovery of 
patients suffering from SCI.  
Though our insight concerning the underlying cellular and biochemical mechanisms of spinal 
cord injury needs to be broadened and translational medicine has to meet many challenges 
such as finding applicable forms of delivering genes like STAT3, there is increasing reason to 
believe that spinal cord injury might at some point be a disease one can treat.  
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